advertisement

List of abstracts related to

Listed by Classification

11.16 Vehicles, delivery systems, pharmacokinetics, formulation (2607 abstracts found)

94838 Relationship between OSDI score and biomicroscopic ocular surface damages in glaucomatous patients treated with preserved antiglaucomatous eye drops
Lajmi H
Journal Français d'Ophtalmologie 2021; 44: 1326-1331 (IGR: 22-2)

94855 Distribution of Gold Nanoparticles in the Anterior Chamber of the Eye after Intracameral Injection for Glaucoma Therapy
Sonntag T
Pharmaceutics 2021; 13: (IGR: 22-2)

94413 Comparison of Topical Instillation From Single-dose and Multidose Eye Drop Containers in Glaucoma: A Multicenter Randomized Cross-sectional Trial
Aptel F
Journal of Glaucoma 2021; 30: 718-724 (IGR: 22-2)

94955 Surface Engineering of FLT4-Targeted Nanocarriers Enhances Cell-Softening Glaucoma Therapy
Vincent MP
ACS applied materials & interfaces 2021; 13: 32823-32836 (IGR: 22-2)

94766 A Review on Newer Ocular Drug Delivery Systems with an Emphasis on Glaucoma
Peter M
Advanced pharmaceutical bulletin 2021; 11: 399-413 (IGR: 22-2)

94436 Cyclodextrin-based formulation of carbonic anhydrase inhibitors for ocular delivery - A review
Jansook P
International Journal of Pharmaceutics 2021; 606: 120955 (IGR: 22-2)

94980 Nano-in-Nano Dendrimer Gel Particles for Efficient Topical Delivery of Antiglaucoma Drugs into the Eye
Wang J
Chemical engineering journal (Lausanne, Switzerland : 1996) 2021; 425: (IGR: 22-2)

94856 Risk Factors for Ocular Surface Disease in Tunisian Users of Preserved Antiglaucomatous Eye Drops
Lajmi H
Journal of current ophthalmology 2021; 33: 128-135 (IGR: 22-2)

94821 Phase Transition Microemulsion of Brimonidine Tartrate for Glaucoma Therapy: Preparation, Characterization and Pharmacodynamic Study
Gautam N
Current Eye Research 2021; 0: 1-9 (IGR: 22-2)

94845 Efficacy and Safety of Preservative-free Latanoprost Eyedrops Compared with Preserved Prostaglandin Analogues in Patients with Open-angle Glaucoma
Seong HJ
Korean Journal of Ophthalmology 2021; 35: 235-241 (IGR: 22-2)

94547 European real-world data about the use of a new delivery system containing a preservative-free multi-dose glaucoma treatment
Denis P
European Journal of Ophthalmology 2021; 31: 1056-1063 (IGR: 22-2)

94930 Gamma sterilization and in vivo evaluation of cationic nanostructured lipid carriers as potential ocular delivery systems for antiglaucoma drugs
Youshia J
European Journal of Pharmaceutical Sciences 2021; 163: 105887 (IGR: 22-2)

94980 Nano-in-Nano Dendrimer Gel Particles for Efficient Topical Delivery of Antiglaucoma Drugs into the Eye
Li B
Chemical engineering journal (Lausanne, Switzerland : 1996) 2021; 425: (IGR: 22-2)

94930 Gamma sterilization and in vivo evaluation of cationic nanostructured lipid carriers as potential ocular delivery systems for antiglaucoma drugs
Kamel AO
European Journal of Pharmaceutical Sciences 2021; 163: 105887 (IGR: 22-2)

94547 European real-world data about the use of a new delivery system containing a preservative-free multi-dose glaucoma treatment
Duch S
European Journal of Ophthalmology 2021; 31: 1056-1063 (IGR: 22-2)

94845 Efficacy and Safety of Preservative-free Latanoprost Eyedrops Compared with Preserved Prostaglandin Analogues in Patients with Open-angle Glaucoma
Lee K
Korean Journal of Ophthalmology 2021; 35: 235-241 (IGR: 22-2)

94855 Distribution of Gold Nanoparticles in the Anterior Chamber of the Eye after Intracameral Injection for Glaucoma Therapy
Froemel F
Pharmaceutics 2021; 13: (IGR: 22-2)

94766 A Review on Newer Ocular Drug Delivery Systems with an Emphasis on Glaucoma
Panonnummal R
Advanced pharmaceutical bulletin 2021; 11: 399-413 (IGR: 22-2)

94955 Surface Engineering of FLT4-Targeted Nanocarriers Enhances Cell-Softening Glaucoma Therapy
Stack T
ACS applied materials & interfaces 2021; 13: 32823-32836 (IGR: 22-2)

94436 Cyclodextrin-based formulation of carbonic anhydrase inhibitors for ocular delivery - A review
Hnin HM
International Journal of Pharmaceutics 2021; 606: 120955 (IGR: 22-2)

94413 Comparison of Topical Instillation From Single-dose and Multidose Eye Drop Containers in Glaucoma: A Multicenter Randomized Cross-sectional Trial
Villemont AS
Journal of Glaucoma 2021; 30: 718-724 (IGR: 22-2)

94838 Relationship between OSDI score and biomicroscopic ocular surface damages in glaucomatous patients treated with preserved antiglaucomatous eye drops
Chelly Z
Journal Français d'Ophtalmologie 2021; 44: 1326-1331 (IGR: 22-2)

94856 Risk Factors for Ocular Surface Disease in Tunisian Users of Preserved Antiglaucomatous Eye Drops
Hmaied W
Journal of current ophthalmology 2021; 33: 128-135 (IGR: 22-2)

94821 Phase Transition Microemulsion of Brimonidine Tartrate for Glaucoma Therapy: Preparation, Characterization and Pharmacodynamic Study
Kesavan K
Current Eye Research 2021; 0: 1-9 (IGR: 22-2)

94855 Distribution of Gold Nanoparticles in the Anterior Chamber of the Eye after Intracameral Injection for Glaucoma Therapy
Stamer WD
Pharmaceutics 2021; 13: (IGR: 22-2)

94547 European real-world data about the use of a new delivery system containing a preservative-free multi-dose glaucoma treatment
Chen E
European Journal of Ophthalmology 2021; 31: 1056-1063 (IGR: 22-2)

94856 Risk Factors for Ocular Surface Disease in Tunisian Users of Preserved Antiglaucomatous Eye Drops
Achour BB
Journal of current ophthalmology 2021; 33: 128-135 (IGR: 22-2)

94413 Comparison of Topical Instillation From Single-dose and Multidose Eye Drop Containers in Glaucoma: A Multicenter Randomized Cross-sectional Trial
Cunnac P
Journal of Glaucoma 2021; 30: 718-724 (IGR: 22-2)

94930 Gamma sterilization and in vivo evaluation of cationic nanostructured lipid carriers as potential ocular delivery systems for antiglaucoma drugs
El Shamy A
European Journal of Pharmaceutical Sciences 2021; 163: 105887 (IGR: 22-2)

94436 Cyclodextrin-based formulation of carbonic anhydrase inhibitors for ocular delivery - A review
Loftsson T
International Journal of Pharmaceutics 2021; 606: 120955 (IGR: 22-2)

94838 Relationship between OSDI score and biomicroscopic ocular surface damages in glaucomatous patients treated with preserved antiglaucomatous eye drops
Choura R
Journal Français d'Ophtalmologie 2021; 44: 1326-1331 (IGR: 22-2)

94980 Nano-in-Nano Dendrimer Gel Particles for Efficient Topical Delivery of Antiglaucoma Drugs into the Eye
Huang D
Chemical engineering journal (Lausanne, Switzerland : 1996) 2021; 425: (IGR: 22-2)

94955 Surface Engineering of FLT4-Targeted Nanocarriers Enhances Cell-Softening Glaucoma Therapy
Vahabikashi A
ACS applied materials & interfaces 2021; 13: 32823-32836 (IGR: 22-2)

94845 Efficacy and Safety of Preservative-free Latanoprost Eyedrops Compared with Preserved Prostaglandin Analogues in Patients with Open-angle Glaucoma
Lee SJ
Korean Journal of Ophthalmology 2021; 35: 235-241 (IGR: 22-2)

94856 Risk Factors for Ocular Surface Disease in Tunisian Users of Preserved Antiglaucomatous Eye Drops
Zahaf A
Journal of current ophthalmology 2021; 33: 128-135 (IGR: 22-2)

94838 Relationship between OSDI score and biomicroscopic ocular surface damages in glaucomatous patients treated with preserved antiglaucomatous eye drops
Mansour KB
Journal Français d'Ophtalmologie 2021; 44: 1326-1331 (IGR: 22-2)

94855 Distribution of Gold Nanoparticles in the Anterior Chamber of the Eye after Intracameral Injection for Glaucoma Therapy
Ohlmann A
Pharmaceutics 2021; 13: (IGR: 22-2)

94955 Surface Engineering of FLT4-Targeted Nanocarriers Enhances Cell-Softening Glaucoma Therapy
Li G
ACS applied materials & interfaces 2021; 13: 32823-32836 (IGR: 22-2)

94980 Nano-in-Nano Dendrimer Gel Particles for Efficient Topical Delivery of Antiglaucoma Drugs into the Eye
Norat P
Chemical engineering journal (Lausanne, Switzerland : 1996) 2021; 425: (IGR: 22-2)

94413 Comparison of Topical Instillation From Single-dose and Multidose Eye Drop Containers in Glaucoma: A Multicenter Randomized Cross-sectional Trial
Sallit R
Journal of Glaucoma 2021; 30: 718-724 (IGR: 22-2)

94845 Efficacy and Safety of Preservative-free Latanoprost Eyedrops Compared with Preserved Prostaglandin Analogues in Patients with Open-angle Glaucoma
Kim S
Korean Journal of Ophthalmology 2021; 35: 235-241 (IGR: 22-2)

94930 Gamma sterilization and in vivo evaluation of cationic nanostructured lipid carriers as potential ocular delivery systems for antiglaucoma drugs
Mansour S
European Journal of Pharmaceutical Sciences 2021; 163: 105887 (IGR: 22-2)

94547 European real-world data about the use of a new delivery system containing a preservative-free multi-dose glaucoma treatment
Klyve P
European Journal of Ophthalmology 2021; 31: 1056-1063 (IGR: 22-2)

94436 Cyclodextrin-based formulation of carbonic anhydrase inhibitors for ocular delivery - A review
Stefánsson E
International Journal of Pharmaceutics 2021; 606: 120955 (IGR: 22-2)

94547 European real-world data about the use of a new delivery system containing a preservative-free multi-dose glaucoma treatment
Skov J
European Journal of Ophthalmology 2021; 31: 1056-1063 (IGR: 22-2)

94413 Comparison of Topical Instillation From Single-dose and Multidose Eye Drop Containers in Glaucoma: A Multicenter Randomized Cross-sectional Trial
Rabilloud M
Journal of Glaucoma 2021; 30: 718-724 (IGR: 22-2)

94845 Efficacy and Safety of Preservative-free Latanoprost Eyedrops Compared with Preserved Prostaglandin Analogues in Patients with Open-angle Glaucoma
Park JW
Korean Journal of Ophthalmology 2021; 35: 235-241 (IGR: 22-2)

94838 Relationship between OSDI score and biomicroscopic ocular surface damages in glaucomatous patients treated with preserved antiglaucomatous eye drops
Hmaied W
Journal Français d'Ophtalmologie 2021; 44: 1326-1331 (IGR: 22-2)

94855 Distribution of Gold Nanoparticles in the Anterior Chamber of the Eye after Intracameral Injection for Glaucoma Therapy
Fuchshofer R
Pharmaceutics 2021; 13: (IGR: 22-2)

94955 Surface Engineering of FLT4-Targeted Nanocarriers Enhances Cell-Softening Glaucoma Therapy
Perkumas KM
ACS applied materials & interfaces 2021; 13: 32823-32836 (IGR: 22-2)

94980 Nano-in-Nano Dendrimer Gel Particles for Efficient Topical Delivery of Antiglaucoma Drugs into the Eye
Grannonico M; Cooper RC
Chemical engineering journal (Lausanne, Switzerland : 1996) 2021; 425: (IGR: 22-2)

94955 Surface Engineering of FLT4-Targeted Nanocarriers Enhances Cell-Softening Glaucoma Therapy
Ren R
ACS applied materials & interfaces 2021; 13: 32823-32836 (IGR: 22-2)

94547 European real-world data about the use of a new delivery system containing a preservative-free multi-dose glaucoma treatment
Puska P
European Journal of Ophthalmology 2021; 31: 1056-1063 (IGR: 22-2)

94855 Distribution of Gold Nanoparticles in the Anterior Chamber of the Eye after Intracameral Injection for Glaucoma Therapy
Breunig M
Pharmaceutics 2021; 13: (IGR: 22-2)

94413 Comparison of Topical Instillation From Single-dose and Multidose Eye Drop Containers in Glaucoma: A Multicenter Randomized Cross-sectional Trial
Poli M; Denis P
Journal of Glaucoma 2021; 30: 718-724 (IGR: 22-2)

94955 Surface Engineering of FLT4-Targeted Nanocarriers Enhances Cell-Softening Glaucoma Therapy
Gong H
ACS applied materials & interfaces 2021; 13: 32823-32836 (IGR: 22-2)

94547 European real-world data about the use of a new delivery system containing a preservative-free multi-dose glaucoma treatment
Erb C
European Journal of Ophthalmology 2021; 31: 1056-1063 (IGR: 22-2)

94980 Nano-in-Nano Dendrimer Gel Particles for Efficient Topical Delivery of Antiglaucoma Drugs into the Eye
Gui Q
Chemical engineering journal (Lausanne, Switzerland : 1996) 2021; 425: (IGR: 22-2)

94955 Surface Engineering of FLT4-Targeted Nanocarriers Enhances Cell-Softening Glaucoma Therapy
Stamer WD
ACS applied materials & interfaces 2021; 13: 32823-32836 (IGR: 22-2)

94980 Nano-in-Nano Dendrimer Gel Particles for Efficient Topical Delivery of Antiglaucoma Drugs into the Eye
Chow WN
Chemical engineering journal (Lausanne, Switzerland : 1996) 2021; 425: (IGR: 22-2)

94955 Surface Engineering of FLT4-Targeted Nanocarriers Enhances Cell-Softening Glaucoma Therapy
Johnson M
ACS applied materials & interfaces 2021; 13: 32823-32836 (IGR: 22-2)

94980 Nano-in-Nano Dendrimer Gel Particles for Efficient Topical Delivery of Antiglaucoma Drugs into the Eye
Liu X
Chemical engineering journal (Lausanne, Switzerland : 1996) 2021; 425: (IGR: 22-2)

94955 Surface Engineering of FLT4-Targeted Nanocarriers Enhances Cell-Softening Glaucoma Therapy
Scott EA
ACS applied materials & interfaces 2021; 13: 32823-32836 (IGR: 22-2)

94980 Nano-in-Nano Dendrimer Gel Particles for Efficient Topical Delivery of Antiglaucoma Drugs into the Eye
Yang H
Chemical engineering journal (Lausanne, Switzerland : 1996) 2021; 425: (IGR: 22-2)

92812 Pharmacokinetics and Pharmacology of Latanoprost 0.005% without Benzalkonium Chloride Vs Latanoprost 0.005% with Benzalkonium Chloride in New Zealand White Rabbits and Beagles
Halder A
Current Eye Research 2021; 46: 1031-1037 (IGR: 22-1)

92251 Latanoprost-loaded phytantriol cubosomes for the treatment of glaucoma
Bessone CDV
European Journal of Pharmaceutical Sciences 2021; 160: 105748 (IGR: 22-1)

92121 Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: UK and Ireland Results from the VISIONARY Study
Ansari E
Advances in Therapy 2021; 38: 2990-3002 (IGR: 22-1)

92597 Optimization and Characterization of Brimonidine Tartrate Nanoparticles-loaded In Situ Gel for the Treatment of Glaucoma
Sharma PK
Current Eye Research 2021; 0: 1-14 (IGR: 22-1)

92066 Dry eye disease among Glaucoma patients on topical hypotensive medications, in a tertiary hospital, Ethiopia
Sahlu M
BMC Ophthalmology 2021; 21: 155 (IGR: 22-1)

92175 Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis
Harasymowycz P
Advances in Therapy 2021; 38: 3019-3031 (IGR: 22-1)

92109 Corneal epithelium and limbal region alterations due to glaucoma medications evaluated by anterior segment optic coherence tomography: a case-control study
Güçlü H
Cutaneous and Ocular Toxicology 2021; 40: 85-94 (IGR: 22-1)

92598 Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost
Erb C
Clinical Ophthalmology 2021; 15: 931-938 (IGR: 22-1)

92528 Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles
Schnichels S
ACS applied materials & interfaces 2021; 13: 9445-9456 (IGR: 22-1)

92630 Formulation and Characterization of Acetazolamide/Carvedilol Niosomal Gel for Glaucoma Treatment: In Vitro, and In Vivo Study
Abdelmonem R
Pharmaceutics 2021; 13: (IGR: 22-1)

92432 A miRNA stabilizing polydopamine nano-platform for intraocular delivery of miR-21-5p in glaucoma therapy
Tan C
Journal of materials chemistry. B 2021; 9: 3335-3345 (IGR: 22-1)

92288 Betaxolol-loaded niosomes integrated within pH-sensitive in situ forming gel for management of glaucoma
Allam A
International Journal of Pharmaceutics 2021; 598: 120380 (IGR: 22-1)

91911 Advances in medical therapy for glaucoma
Ostler E
Current Opinions in Ophthalmology 2021; 32: 129-133 (IGR: 22-1)

92071 New strategies for the management of ocular surface disease in glaucoma patients
Voicu L
Current Opinions in Ophthalmology 2021; 32: 134-140 (IGR: 22-1)

92487 Comparison of the Intraocular Pressure-Lowering Effect and Safety of Preservative-Free And Preservative-Containing Brimonidine/Timolol Fixed-Combination Ophthalmic Solutions in Patients with Open-Angle Glaucoma
Kim JM
Seminars in Ophthalmology 2021; 36: 103-109 (IGR: 22-1)

92043 Nanomedicines for the treatment of glaucoma: Current status and future perspectives
Zhai Z
Acta biomaterialia 2021; 125: 41-56 (IGR: 22-1)

92224 Targeted delivery of LM22A-4 by cubosomes protects retinal ganglion cells in an experimental glaucoma model
Ding Y
Acta biomaterialia 2021; 126: 433-444 (IGR: 22-1)

92175 Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis
Hutnik C
Advances in Therapy 2021; 38: 3019-3031 (IGR: 22-1)

92528 Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles
Hurst J
ACS applied materials & interfaces 2021; 13: 9445-9456 (IGR: 22-1)

92224 Targeted delivery of LM22A-4 by cubosomes protects retinal ganglion cells in an experimental glaucoma model
Chow SH
Acta biomaterialia 2021; 126: 433-444 (IGR: 22-1)

92432 A miRNA stabilizing polydopamine nano-platform for intraocular delivery of miR-21-5p in glaucoma therapy
Jia F
Journal of materials chemistry. B 2021; 9: 3335-3345 (IGR: 22-1)

92043 Nanomedicines for the treatment of glaucoma: Current status and future perspectives
Cheng Y
Acta biomaterialia 2021; 125: 41-56 (IGR: 22-1)

92251 Latanoprost-loaded phytantriol cubosomes for the treatment of glaucoma
Akhlaghi SP
European Journal of Pharmaceutical Sciences 2021; 160: 105748 (IGR: 22-1)

92487 Comparison of the Intraocular Pressure-Lowering Effect and Safety of Preservative-Free And Preservative-Containing Brimonidine/Timolol Fixed-Combination Ophthalmic Solutions in Patients with Open-Angle Glaucoma
Kim TW
Seminars in Ophthalmology 2021; 36: 103-109 (IGR: 22-1)

91911 Advances in medical therapy for glaucoma
Rhee D
Current Opinions in Ophthalmology 2021; 32: 129-133 (IGR: 22-1)

92066 Dry eye disease among Glaucoma patients on topical hypotensive medications, in a tertiary hospital, Ethiopia
Giorgis AT
BMC Ophthalmology 2021; 21: 155 (IGR: 22-1)

92598 Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost
Stalmans I
Clinical Ophthalmology 2021; 15: 931-938 (IGR: 22-1)

92288 Betaxolol-loaded niosomes integrated within pH-sensitive in situ forming gel for management of glaucoma
Elsabahy M
International Journal of Pharmaceutics 2021; 598: 120380 (IGR: 22-1)

92812 Pharmacokinetics and Pharmacology of Latanoprost 0.005% without Benzalkonium Chloride Vs Latanoprost 0.005% with Benzalkonium Chloride in New Zealand White Rabbits and Beagles
Khopade AJ
Current Eye Research 2021; 46: 1031-1037 (IGR: 22-1)

92109 Corneal epithelium and limbal region alterations due to glaucoma medications evaluated by anterior segment optic coherence tomography: a case-control study
Çınar AK
Cutaneous and Ocular Toxicology 2021; 40: 85-94 (IGR: 22-1)

92121 Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: UK and Ireland Results from the VISIONARY Study
Pavicic-Astalos J
Advances in Therapy 2021; 38: 2990-3002 (IGR: 22-1)

92597 Optimization and Characterization of Brimonidine Tartrate Nanoparticles-loaded In Situ Gel for the Treatment of Glaucoma
Chauhan MK
Current Eye Research 2021; 0: 1-14 (IGR: 22-1)

92630 Formulation and Characterization of Acetazolamide/Carvedilol Niosomal Gel for Glaucoma Treatment: In Vitro, and In Vivo Study
Elhabal SF
Pharmaceutics 2021; 13: (IGR: 22-1)

92071 New strategies for the management of ocular surface disease in glaucoma patients
Salim S
Current Opinions in Ophthalmology 2021; 32: 134-140 (IGR: 22-1)

92043 Nanomedicines for the treatment of glaucoma: Current status and future perspectives
Hong J
Acta biomaterialia 2021; 125: 41-56 (IGR: 22-1)

92109 Corneal epithelium and limbal region alterations due to glaucoma medications evaluated by anterior segment optic coherence tomography: a case-control study
Çınar AC
Cutaneous and Ocular Toxicology 2021; 40: 85-94 (IGR: 22-1)

92630 Formulation and Characterization of Acetazolamide/Carvedilol Niosomal Gel for Glaucoma Treatment: In Vitro, and In Vivo Study
Abdelmalak NS
Pharmaceutics 2021; 13: (IGR: 22-1)

92288 Betaxolol-loaded niosomes integrated within pH-sensitive in situ forming gel for management of glaucoma
El Badry M
International Journal of Pharmaceutics 2021; 598: 120380 (IGR: 22-1)

92432 A miRNA stabilizing polydopamine nano-platform for intraocular delivery of miR-21-5p in glaucoma therapy
Zhang P
Journal of materials chemistry. B 2021; 9: 3335-3345 (IGR: 22-1)

92251 Latanoprost-loaded phytantriol cubosomes for the treatment of glaucoma
Tártara LI
European Journal of Pharmaceutical Sciences 2021; 160: 105748 (IGR: 22-1)

92224 Targeted delivery of LM22A-4 by cubosomes protects retinal ganglion cells in an experimental glaucoma model
Chen J
Acta biomaterialia 2021; 126: 433-444 (IGR: 22-1)

92121 Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: UK and Ireland Results from the VISIONARY Study
Ayan F
Advances in Therapy 2021; 38: 2990-3002 (IGR: 22-1)

92598 Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost
Iliev M
Clinical Ophthalmology 2021; 15: 931-938 (IGR: 22-1)

92487 Comparison of the Intraocular Pressure-Lowering Effect and Safety of Preservative-Free And Preservative-Containing Brimonidine/Timolol Fixed-Combination Ophthalmic Solutions in Patients with Open-Angle Glaucoma
Park SW
Seminars in Ophthalmology 2021; 36: 103-109 (IGR: 22-1)

92528 Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles
de Vries JW
ACS applied materials & interfaces 2021; 13: 9445-9456 (IGR: 22-1)

91911 Advances in medical therapy for glaucoma
Burney E
Current Opinions in Ophthalmology 2021; 32: 129-133 (IGR: 22-1)

92175 Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis
Rouland JF
Advances in Therapy 2021; 38: 3019-3031 (IGR: 22-1)

92598 Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost
Muñoz-Negrete FJ
Clinical Ophthalmology 2021; 15: 931-938 (IGR: 22-1)

91911 Advances in medical therapy for glaucoma
Sozeri Y
Current Opinions in Ophthalmology 2021; 32: 129-133 (IGR: 22-1)

92487 Comparison of the Intraocular Pressure-Lowering Effect and Safety of Preservative-Free And Preservative-Containing Brimonidine/Timolol Fixed-Combination Ophthalmic Solutions in Patients with Open-Angle Glaucoma
Park HL
Seminars in Ophthalmology 2021; 36: 103-109 (IGR: 22-1)

92432 A miRNA stabilizing polydopamine nano-platform for intraocular delivery of miR-21-5p in glaucoma therapy
Sun X
Journal of materials chemistry. B 2021; 9: 3335-3345 (IGR: 22-1)

92224 Targeted delivery of LM22A-4 by cubosomes protects retinal ganglion cells in an experimental glaucoma model
Brun APL
Acta biomaterialia 2021; 126: 433-444 (IGR: 22-1)

92121 Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: UK and Ireland Results from the VISIONARY Study
King AJ
Advances in Therapy 2021; 38: 2990-3002 (IGR: 22-1)

92109 Corneal epithelium and limbal region alterations due to glaucoma medications evaluated by anterior segment optic coherence tomography: a case-control study
Akaray İ
Cutaneous and Ocular Toxicology 2021; 40: 85-94 (IGR: 22-1)

92175 Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis
Negrete FJM
Advances in Therapy 2021; 38: 3019-3031 (IGR: 22-1)

92630 Formulation and Characterization of Acetazolamide/Carvedilol Niosomal Gel for Glaucoma Treatment: In Vitro, and In Vivo Study
El-Nabarawi MA
Pharmaceutics 2021; 13: (IGR: 22-1)

92528 Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles
Ullah S
ACS applied materials & interfaces 2021; 13: 9445-9456 (IGR: 22-1)

92251 Latanoprost-loaded phytantriol cubosomes for the treatment of glaucoma
Quinteros DA
European Journal of Pharmaceutical Sciences 2021; 160: 105748 (IGR: 22-1)

92288 Betaxolol-loaded niosomes integrated within pH-sensitive in situ forming gel for management of glaucoma
Eleraky NE
International Journal of Pharmaceutics 2021; 598: 120380 (IGR: 22-1)

92630 Formulation and Characterization of Acetazolamide/Carvedilol Niosomal Gel for Glaucoma Treatment: In Vitro, and In Vivo Study
Teaima MH
Pharmaceutics 2021; 13: (IGR: 22-1)

92109 Corneal epithelium and limbal region alterations due to glaucoma medications evaluated by anterior segment optic coherence tomography: a case-control study
Şambel Aykutlu M
Cutaneous and Ocular Toxicology 2021; 40: 85-94 (IGR: 22-1)

92528 Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles
Frößl K
ACS applied materials & interfaces 2021; 13: 9445-9456 (IGR: 22-1)

92224 Targeted delivery of LM22A-4 by cubosomes protects retinal ganglion cells in an experimental glaucoma model
Wu CM
Acta biomaterialia 2021; 126: 433-444 (IGR: 22-1)

92487 Comparison of the Intraocular Pressure-Lowering Effect and Safety of Preservative-Free And Preservative-Containing Brimonidine/Timolol Fixed-Combination Ophthalmic Solutions in Patients with Open-Angle Glaucoma
Hwang YH
Seminars in Ophthalmology 2021; 36: 103-109 (IGR: 22-1)

92432 A miRNA stabilizing polydopamine nano-platform for intraocular delivery of miR-21-5p in glaucoma therapy
Qiao Y
Journal of materials chemistry. B 2021; 9: 3335-3345 (IGR: 22-1)

92251 Latanoprost-loaded phytantriol cubosomes for the treatment of glaucoma
Loh W
European Journal of Pharmaceutical Sciences 2021; 160: 105748 (IGR: 22-1)

92175 Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis
Economou MA
Advances in Therapy 2021; 38: 3019-3031 (IGR: 22-1)

92121 Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: UK and Ireland Results from the VISIONARY Study
Kinsella M
Advances in Therapy 2021; 38: 2990-3002 (IGR: 22-1)

92432 A miRNA stabilizing polydopamine nano-platform for intraocular delivery of miR-21-5p in glaucoma therapy
Chen X
Journal of materials chemistry. B 2021; 9: 3335-3345 (IGR: 22-1)

92251 Latanoprost-loaded phytantriol cubosomes for the treatment of glaucoma
Allemandi DA
European Journal of Pharmaceutical Sciences 2021; 160: 105748 (IGR: 22-1)

92121 Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: UK and Ireland Results from the VISIONARY Study
Ng E
Advances in Therapy 2021; 38: 2990-3002 (IGR: 22-1)

92528 Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles
Gruszka A
ACS applied materials & interfaces 2021; 13: 9445-9456 (IGR: 22-1)

92175 Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis
Denis P
Advances in Therapy 2021; 38: 3019-3031 (IGR: 22-1)

92109 Corneal epithelium and limbal region alterations due to glaucoma medications evaluated by anterior segment optic coherence tomography: a case-control study
Sakallıoğlu AK
Cutaneous and Ocular Toxicology 2021; 40: 85-94 (IGR: 22-1)

92224 Targeted delivery of LM22A-4 by cubosomes protects retinal ganglion cells in an experimental glaucoma model
Duff AP
Acta biomaterialia 2021; 126: 433-444 (IGR: 22-1)

92487 Comparison of the Intraocular Pressure-Lowering Effect and Safety of Preservative-Free And Preservative-Containing Brimonidine/Timolol Fixed-Combination Ophthalmic Solutions in Patients with Open-Angle Glaucoma
Jeoung JW; Kim CY
Seminars in Ophthalmology 2021; 36: 103-109 (IGR: 22-1)

92175 Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis
Baudouin C
Advances in Therapy 2021; 38: 3019-3031 (IGR: 22-1)

92224 Targeted delivery of LM22A-4 by cubosomes protects retinal ganglion cells in an experimental glaucoma model
Wang Y
Acta biomaterialia 2021; 126: 433-444 (IGR: 22-1)

92121 Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: UK and Ireland Results from the VISIONARY Study
Nita A
Advances in Therapy 2021; 38: 2990-3002 (IGR: 22-1)

92432 A miRNA stabilizing polydopamine nano-platform for intraocular delivery of miR-21-5p in glaucoma therapy
Wang Y
Journal of materials chemistry. B 2021; 9: 3335-3345 (IGR: 22-1)

92109 Corneal epithelium and limbal region alterations due to glaucoma medications evaluated by anterior segment optic coherence tomography: a case-control study
Gürlü V
Cutaneous and Ocular Toxicology 2021; 40: 85-94 (IGR: 22-1)

92528 Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles
Löscher M
ACS applied materials & interfaces 2021; 13: 9445-9456 (IGR: 22-1)

92432 A miRNA stabilizing polydopamine nano-platform for intraocular delivery of miR-21-5p in glaucoma therapy
Chen J
Journal of materials chemistry. B 2021; 9: 3335-3345 (IGR: 22-1)

92121 Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: UK and Ireland Results from the VISIONARY Study

Advances in Therapy 2021; 38: 2990-3002 (IGR: 22-1)

92528 Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles
Bartz-Schmidt KU
ACS applied materials & interfaces 2021; 13: 9445-9456 (IGR: 22-1)

92224 Targeted delivery of LM22A-4 by cubosomes protects retinal ganglion cells in an experimental glaucoma model
Song J; Wang JH
Acta biomaterialia 2021; 126: 433-444 (IGR: 22-1)

92528 Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles
Spitzer MS
ACS applied materials & interfaces 2021; 13: 9445-9456 (IGR: 22-1)

92432 A miRNA stabilizing polydopamine nano-platform for intraocular delivery of miR-21-5p in glaucoma therapy
Lei Y
Journal of materials chemistry. B 2021; 9: 3335-3345 (IGR: 22-1)

92528 Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles
Herrmann A
ACS applied materials & interfaces 2021; 13: 9445-9456 (IGR: 22-1)

92224 Targeted delivery of LM22A-4 by cubosomes protects retinal ganglion cells in an experimental glaucoma model
Wong VHY; Zhao D; Nishimura T; Lee TH; Conn CE; Hsu HY; Bui BV; Liu GS; Shen HH
Acta biomaterialia 2021; 126: 433-444 (IGR: 22-1)

91725 Physiochemical Properties and Cytotoxicity of a Benzalkonium Chloride-Free, Micellar Emulsion Ophthalmic Formulation of Latanoprost
Halder A
Clinical Ophthalmology 2020; 14: 3057-3064 (IGR: 21-4)

91266 Assessment of Corneal Epithelium Thickness in Glaucomatous Patients Undergoing Medical Treatment
Halkiadakis I
Journal of Glaucoma 2021; 30: 44-49 (IGR: 21-4)

91413 Sustained-release drug delivery systems for the treatment of glaucoma
Kesav NP
International Journal of Ophthalmology 2021; 14: 148-159 (IGR: 21-4)

91799 Novel Eye Drop Delivery Aid Improves Outcomes and Satisfaction
Sanchez FG
Ophthalmology. Glaucoma 2021; 0: (IGR: 21-4)

91648 Assessment of ocular surface disease in glaucoma patients with benzalkonium chloride-preserved latanoprost eye drops: a short-term longitudinal study
Su CC
Graefe's Archive for Clinical and Experimental Ophthalmology 2021; 259: 1243-1251 (IGR: 21-4)

91202 Effect of Autologous Serum Eyedrops on Ocular Surface Disease Caused by Preserved Glaucoma Eyedrops
So HR
Journal of clinical medicine 2020; 9: (IGR: 21-4)

91695 Effects of Benzalkonium Chloride in Ophthalmic Eyedrop Medications on Corneal Epithelium
Seino S
Yakugaku Zasshi 2021; 141: 35-39 (IGR: 21-4)

91819 Topical preservative-free ophthalmic treatments: an unmet clinical need
Figus M
Expert Opinion on Drug Delivery 2020; 0: 1-18 (IGR: 21-4)

90921 Glaucoma: Management and Future Perspectives for Nanotechnology-Based Treatment Modalities
El Hoffy NM
European Journal of Pharmaceutical Sciences 2021; 158: 105648 (IGR: 21-4)

90987 Understanding the Dual Dilemma of Dry Eye and Glaucoma: An International Review
Nijm LM
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2020; 9: 481-490 (IGR: 21-4)

91669 Topical Bimatoprost Insert for Primary Open-Angle Glaucoma and Ocular Hypertension Treatment - A Phase II Controlled Study
Rubião F
Current Drug Delivery 2020; 0: (IGR: 21-4)

91260 Assessment of Ocular Surface Disease in Glaucoma Patients in Ghana
Kobia-Acquah E
Journal of Glaucoma 2021; 30: 180-186 (IGR: 21-4)

91577 Patients' Experience of Using Eye Drop Guide Device to Aid Self-Administration of Glaucoma Medications
Sakiyalak D
Clinical Ophthalmology 2020; 14: 3781-3788 (IGR: 21-4)

91324 Effect of preservative-free and preserved prostaglandin analogues on the histology of cornea of adult male Guinea pigs following repeated exposure
Ali AF
Folia morphologica 2022; 81: 52-64 (IGR: 21-4)

91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Rodrigo MJ
Biomaterials science 2020; 8: 6246-6260 (IGR: 21-4)

91553 Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions
Rahić O
Pharmaceutics 2020; 13: (IGR: 21-4)

91342 THE EFFECT OF THERAPY ON THE OCULAR SURFACE IN PATIENTS WITH UNILATERAL PEDIATRIC GLAUCOMA Purpose: The aim of the study was to evaluate ocular surface and
Janderová M
?eska a Slovenska Oftalmologie 2021; 77: 28-34 (IGR: 21-4)

91846 Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure
Lorenzo-Soler L
Acta Ophthalmologica 2021; 99: 376-382 (IGR: 21-4)

91252 Soft Contact Lens with Embedded Microtubes for Sustained and Self-Adaptive Drug Delivery for Glaucoma Treatment
Ding X
ACS applied materials & interfaces 2020; 12: 45789-45795 (IGR: 21-4)

91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Rodrigo MJ
Biomaterials science 2020; 8: 6246-6260 (IGR: 21-4)

91474 The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability
Konstas AG
Expert Opinion on Drug Safety 2021; 0: 1-14 (IGR: 21-4)

90873 Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1)
Medeiros FA
Ophthalmology 2020; 127: 1627-1641 (IGR: 21-4)

91624 Signs and Symptoms of Ocular Surface Disease: The Reasons for Patient Dissatisfaction with Glaucoma Treatments
Stalmans I
Clinical Ophthalmology 2020; 14: 3675-3680 (IGR: 21-4)

91447 Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
Ruangvaravate N
Clinical Ophthalmology 2020; 14: 3109-3119 (IGR: 21-4)

91799 Novel Eye Drop Delivery Aid Improves Outcomes and Satisfaction
Sanchez FG
Ophthalmology. Glaucoma 2021; 0: (IGR: 21-4)

91141 A Tenon's capsule/bulbar conjunctiva interface biomimetic to model fibrosis and local drug delivery
Kozdon K
PLoS ONE 2020; 15: e0241569 (IGR: 21-4)

91252 Soft Contact Lens with Embedded Microtubes for Sustained and Self-Adaptive Drug Delivery for Glaucoma Treatment
Ben-Shlomo G
ACS applied materials & interfaces 2020; 12: 45789-45795 (IGR: 21-4)

91553 Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions
Tucak A
Pharmaceutics 2020; 13: (IGR: 21-4)

90873 Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1)
Walters TR
Ophthalmology 2020; 127: 1627-1641 (IGR: 21-4)

91624 Signs and Symptoms of Ocular Surface Disease: The Reasons for Patient Dissatisfaction with Glaucoma Treatments
Lemij H
Clinical Ophthalmology 2020; 14: 3675-3680 (IGR: 21-4)

91447 Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
Choojun K
Clinical Ophthalmology 2020; 14: 3109-3119 (IGR: 21-4)

91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Cardiel MJ
Biomaterials science 2020; 8: 6246-6260 (IGR: 21-4)

91342 THE EFFECT OF THERAPY ON THE OCULAR SURFACE IN PATIENTS WITH UNILATERAL PEDIATRIC GLAUCOMA Purpose: The aim of the study was to evaluate ocular surface and
Filouš A
?eska a Slovenska Oftalmologie 2021; 77: 28-34 (IGR: 21-4)

91773 Formulation and investigation of pilocarpine hydrochloride niosomal gels for the treatment of glaucoma: intraocular pressure measurement in white albino rabbits
Verma A
Drug Delivery 2020; 27: 888-899 (IGR: 21-4)

91577 Patients' Experience of Using Eye Drop Guide Device to Aid Self-Administration of Glaucoma Medications
Kobwanthanakun S
Clinical Ophthalmology 2020; 14: 3781-3788 (IGR: 21-4)

91324 Effect of preservative-free and preserved prostaglandin analogues on the histology of cornea of adult male Guinea pigs following repeated exposure
Salama RM
Folia morphologica 2022; 81: 52-64 (IGR: 21-4)

91846 Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure
Olafsdottir OB
Acta Ophthalmologica 2021; 99: 376-382 (IGR: 21-4)

91648 Assessment of ocular surface disease in glaucoma patients with benzalkonium chloride-preserved latanoprost eye drops: a short-term longitudinal study
Lee YC
Graefe's Archive for Clinical and Experimental Ophthalmology 2021; 259: 1243-1251 (IGR: 21-4)

91141 A Tenon's capsule/bulbar conjunctiva interface biomimetic to model fibrosis and local drug delivery
Caridi B
PLoS ONE 2020; 15: e0241569 (IGR: 21-4)

91695 Effects of Benzalkonium Chloride in Ophthalmic Eyedrop Medications on Corneal Epithelium
Takada Y
Yakugaku Zasshi 2021; 141: 35-39 (IGR: 21-4)

90921 Glaucoma: Management and Future Perspectives for Nanotechnology-Based Treatment Modalities
Abdel Azim EA
European Journal of Pharmaceutical Sciences 2021; 158: 105648 (IGR: 21-4)

91799 Novel Eye Drop Delivery Aid Improves Outcomes and Satisfaction
Mansberger SL
Ophthalmology. Glaucoma 2021; 0: (IGR: 21-4)

90987 Understanding the Dual Dilemma of Dry Eye and Glaucoma: An International Review
de Benito-Llopis L
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2020; 9: 481-490 (IGR: 21-4)

91669 Topical Bimatoprost Insert for Primary Open-Angle Glaucoma and Ocular Hypertension Treatment - A Phase II Controlled Study
Araújo ACF
Current Drug Delivery 2020; 0: (IGR: 21-4)

91725 Physiochemical Properties and Cytotoxicity of a Benzalkonium Chloride-Free, Micellar Emulsion Ophthalmic Formulation of Latanoprost
Khopade AJ
Clinical Ophthalmology 2020; 14: 3057-3064 (IGR: 21-4)

91260 Assessment of Ocular Surface Disease in Glaucoma Patients in Ghana
Gyekye GA
Journal of Glaucoma 2021; 30: 180-186 (IGR: 21-4)

91413 Sustained-release drug delivery systems for the treatment of glaucoma
Young CEC
International Journal of Ophthalmology 2021; 14: 148-159 (IGR: 21-4)

91266 Assessment of Corneal Epithelium Thickness in Glaucomatous Patients Undergoing Medical Treatment
Vernikou A
Journal of Glaucoma 2021; 30: 44-49 (IGR: 21-4)

91202 Effect of Autologous Serum Eyedrops on Ocular Surface Disease Caused by Preserved Glaucoma Eyedrops
Park HYL
Journal of clinical medicine 2020; 9: (IGR: 21-4)

91819 Topical preservative-free ophthalmic treatments: an unmet clinical need
Agnifili L
Expert Opinion on Drug Delivery 2020; 0: 1-18 (IGR: 21-4)

91474 The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability
Labbé A
Expert Opinion on Drug Safety 2021; 0: 1-14 (IGR: 21-4)

91669 Topical Bimatoprost Insert for Primary Open-Angle Glaucoma and Ocular Hypertension Treatment - A Phase II Controlled Study
Sancio JB
Current Drug Delivery 2020; 0: (IGR: 21-4)

91474 The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability
Katsanos A
Expert Opinion on Drug Safety 2021; 0: 1-14 (IGR: 21-4)

90873 Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1)
Kolko M
Ophthalmology 2020; 127: 1627-1641 (IGR: 21-4)

91846 Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure
Garhöfer G
Acta Ophthalmologica 2021; 99: 376-382 (IGR: 21-4)

91141 A Tenon's capsule/bulbar conjunctiva interface biomimetic to model fibrosis and local drug delivery
Duru I
PLoS ONE 2020; 15: e0241569 (IGR: 21-4)

91624 Signs and Symptoms of Ocular Surface Disease: The Reasons for Patient Dissatisfaction with Glaucoma Treatments
Clarke J
Clinical Ophthalmology 2020; 14: 3675-3680 (IGR: 21-4)

91252 Soft Contact Lens with Embedded Microtubes for Sustained and Self-Adaptive Drug Delivery for Glaucoma Treatment
Que L
ACS applied materials & interfaces 2020; 12: 45789-45795 (IGR: 21-4)

91773 Formulation and investigation of pilocarpine hydrochloride niosomal gels for the treatment of glaucoma: intraocular pressure measurement in white albino rabbits
Jain N
Drug Delivery 2020; 27: 888-899 (IGR: 21-4)

91413 Sustained-release drug delivery systems for the treatment of glaucoma
Ertel MK
International Journal of Ophthalmology 2021; 14: 148-159 (IGR: 21-4)

91447 Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
Srikulsasitorn B
Clinical Ophthalmology 2020; 14: 3109-3119 (IGR: 21-4)

91202 Effect of Autologous Serum Eyedrops on Ocular Surface Disease Caused by Preserved Glaucoma Eyedrops
Chung SH
Journal of clinical medicine 2020; 9: (IGR: 21-4)

91260 Assessment of Ocular Surface Disease in Glaucoma Patients in Ghana
Antwi-Adjei EK
Journal of Glaucoma 2021; 30: 180-186 (IGR: 21-4)

91819 Topical preservative-free ophthalmic treatments: an unmet clinical need
Lanzini M
Expert Opinion on Drug Delivery 2020; 0: 1-18 (IGR: 21-4)

91799 Novel Eye Drop Delivery Aid Improves Outcomes and Satisfaction
Kung Y
Ophthalmology. Glaucoma 2021; 0: (IGR: 21-4)

91447 Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
Srikulsasitorn B
Clinical Ophthalmology 2020; 14: 3109-3119 (IGR: 21-4)

91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Fraile JM
Biomaterials science 2020; 8: 6246-6260 (IGR: 21-4)

91695 Effects of Benzalkonium Chloride in Ophthalmic Eyedrop Medications on Corneal Epithelium
Saika S
Yakugaku Zasshi 2021; 141: 35-39 (IGR: 21-4)

91553 Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions
Omerović N
Pharmaceutics 2020; 13: (IGR: 21-4)

91342 THE EFFECT OF THERAPY ON THE OCULAR SURFACE IN PATIENTS WITH UNILATERAL PEDIATRIC GLAUCOMA Purpose: The aim of the study was to evaluate ocular surface and
Hložánek M
?eska a Slovenska Oftalmologie 2021; 77: 28-34 (IGR: 21-4)

90921 Glaucoma: Management and Future Perspectives for Nanotechnology-Based Treatment Modalities
Hathout RM
European Journal of Pharmaceutical Sciences 2021; 158: 105648 (IGR: 21-4)

91266 Assessment of Corneal Epithelium Thickness in Glaucomatous Patients Undergoing Medical Treatment
Tzimis V
Journal of Glaucoma 2021; 30: 44-49 (IGR: 21-4)

91324 Effect of preservative-free and preserved prostaglandin analogues on the histology of cornea of adult male Guinea pigs following repeated exposure
Soliman MA
Folia morphologica 2022; 81: 52-64 (IGR: 21-4)

90987 Understanding the Dual Dilemma of Dry Eye and Glaucoma: An International Review
Rossi GC
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2020; 9: 481-490 (IGR: 21-4)

91648 Assessment of ocular surface disease in glaucoma patients with benzalkonium chloride-preserved latanoprost eye drops: a short-term longitudinal study
Lee PRC
Graefe's Archive for Clinical and Experimental Ophthalmology 2021; 259: 1243-1251 (IGR: 21-4)

91819 Topical preservative-free ophthalmic treatments: an unmet clinical need
Brescia L
Expert Opinion on Drug Delivery 2020; 0: 1-18 (IGR: 21-4)

91413 Sustained-release drug delivery systems for the treatment of glaucoma
Seibold LK
International Journal of Ophthalmology 2021; 14: 148-159 (IGR: 21-4)

91846 Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure
Jansook P
Acta Ophthalmologica 2021; 99: 376-382 (IGR: 21-4)

90987 Understanding the Dual Dilemma of Dry Eye and Glaucoma: An International Review
Vajaranant TS
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2020; 9: 481-490 (IGR: 21-4)

91553 Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions
Sirbubalo M
Pharmaceutics 2020; 13: (IGR: 21-4)

91799 Novel Eye Drop Delivery Aid Improves Outcomes and Satisfaction
Gardiner SK
Ophthalmology. Glaucoma 2021; 0: (IGR: 21-4)

91474 The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability
Meier-Gibbons F
Expert Opinion on Drug Safety 2021; 0: 1-14 (IGR: 21-4)

91266 Assessment of Corneal Epithelium Thickness in Glaucomatous Patients Undergoing Medical Treatment
Markopoulos I
Journal of Glaucoma 2021; 30: 44-49 (IGR: 21-4)

91447 Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
Chokboonpiem J
Clinical Ophthalmology 2020; 14: 3109-3119 (IGR: 21-4)

91202 Effect of Autologous Serum Eyedrops on Ocular Surface Disease Caused by Preserved Glaucoma Eyedrops
Kim HS
Journal of clinical medicine 2020; 9: (IGR: 21-4)

91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Mendez-Martinez S
Biomaterials science 2020; 8: 6246-6260 (IGR: 21-4)

91342 THE EFFECT OF THERAPY ON THE OCULAR SURFACE IN PATIENTS WITH UNILATERAL PEDIATRIC GLAUCOMA Purpose: The aim of the study was to evaluate ocular surface and
Dotřelová D
?eska a Slovenska Oftalmologie 2021; 77: 28-34 (IGR: 21-4)

91669 Topical Bimatoprost Insert for Primary Open-Angle Glaucoma and Ocular Hypertension Treatment - A Phase II Controlled Study
Nogueira BS
Current Drug Delivery 2020; 0: (IGR: 21-4)

91624 Signs and Symptoms of Ocular Surface Disease: The Reasons for Patient Dissatisfaction with Glaucoma Treatments
Baudouin C
Clinical Ophthalmology 2020; 14: 3675-3680 (IGR: 21-4)

91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Mendez-Martinez S
Biomaterials science 2020; 8: 6246-6260 (IGR: 21-4)

90921 Glaucoma: Management and Future Perspectives for Nanotechnology-Based Treatment Modalities
Fouly MA
European Journal of Pharmaceutical Sciences 2021; 158: 105648 (IGR: 21-4)

91141 A Tenon's capsule/bulbar conjunctiva interface biomimetic to model fibrosis and local drug delivery
Ezra DG
PLoS ONE 2020; 15: e0241569 (IGR: 21-4)

91260 Assessment of Ocular Surface Disease in Glaucoma Patients in Ghana
Koomson NY
Journal of Glaucoma 2021; 30: 180-186 (IGR: 21-4)

90873 Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1)
Coote M
Ophthalmology 2020; 127: 1627-1641 (IGR: 21-4)

90921 Glaucoma: Management and Future Perspectives for Nanotechnology-Based Treatment Modalities
Elkheshen SA
European Journal of Pharmaceutical Sciences 2021; 158: 105648 (IGR: 21-4)

91266 Assessment of Corneal Epithelium Thickness in Glaucomatous Patients Undergoing Medical Treatment
Popeskou K
Journal of Glaucoma 2021; 30: 44-49 (IGR: 21-4)

91202 Effect of Autologous Serum Eyedrops on Ocular Surface Disease Caused by Preserved Glaucoma Eyedrops
Byun YS
Journal of clinical medicine 2020; 9: (IGR: 21-4)

91553 Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions
Hindija L
Pharmaceutics 2020; 13: (IGR: 21-4)

90873 Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1)
Bejanian M
Ophthalmology 2020; 127: 1627-1641 (IGR: 21-4)

91819 Topical preservative-free ophthalmic treatments: an unmet clinical need
Sartini F
Expert Opinion on Drug Delivery 2020; 0: 1-18 (IGR: 21-4)

91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Martinez-Rincon T
Biomaterials science 2020; 8: 6246-6260 (IGR: 21-4)

91260 Assessment of Ocular Surface Disease in Glaucoma Patients in Ghana
Cobbina F
Journal of Glaucoma 2021; 30: 180-186 (IGR: 21-4)

91413 Sustained-release drug delivery systems for the treatment of glaucoma
Kahook MY
International Journal of Ophthalmology 2021; 14: 148-159 (IGR: 21-4)

91819 Topical preservative-free ophthalmic treatments: an unmet clinical need
Sartini F
Expert Opinion on Drug Delivery 2020; 0: 1-18 (IGR: 21-4)

90987 Understanding the Dual Dilemma of Dry Eye and Glaucoma: An International Review
Coroneo MT
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2020; 9: 481-490 (IGR: 21-4)

91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Martinez-Rincon T
Biomaterials science 2020; 8: 6246-6260 (IGR: 21-4)

91342 THE EFFECT OF THERAPY ON THE OCULAR SURFACE IN PATIENTS WITH UNILATERAL PEDIATRIC GLAUCOMA Purpose: The aim of the study was to evaluate ocular surface and
Mahelková G
?eska a Slovenska Oftalmologie 2021; 77: 28-34 (IGR: 21-4)

91447 Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
Asanatong D
Clinical Ophthalmology 2020; 14: 3109-3119 (IGR: 21-4)

91141 A Tenon's capsule/bulbar conjunctiva interface biomimetic to model fibrosis and local drug delivery
Phillips JB
PLoS ONE 2020; 15: e0241569 (IGR: 21-4)

91474 The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability
Irkec M
Expert Opinion on Drug Safety 2021; 0: 1-14 (IGR: 21-4)

91624 Signs and Symptoms of Ocular Surface Disease: The Reasons for Patient Dissatisfaction with Glaucoma Treatments

Clinical Ophthalmology 2020; 14: 3675-3680 (IGR: 21-4)

91669 Topical Bimatoprost Insert for Primary Open-Angle Glaucoma and Ocular Hypertension Treatment - A Phase II Controlled Study
Franca JR
Current Drug Delivery 2020; 0: (IGR: 21-4)

91799 Novel Eye Drop Delivery Aid Improves Outcomes and Satisfaction
Burgoyne CF
Ophthalmology. Glaucoma 2021; 0: (IGR: 21-4)

91819 Topical preservative-free ophthalmic treatments: an unmet clinical need
Sartini F
Expert Opinion on Drug Delivery 2020; 0: 1-18 (IGR: 21-4)

91846 Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure
Kristinsdottir IM
Acta Ophthalmologica 2021; 99: 376-382 (IGR: 21-4)

91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Subias M
Biomaterials science 2020; 8: 6246-6260 (IGR: 21-4)

91260 Assessment of Ocular Surface Disease in Glaucoma Patients in Ghana
Donkor R
Journal of Glaucoma 2021; 30: 180-186 (IGR: 21-4)

91799 Novel Eye Drop Delivery Aid Improves Outcomes and Satisfaction
Cunningham ET
Ophthalmology. Glaucoma 2021; 0: (IGR: 21-4)

91141 A Tenon's capsule/bulbar conjunctiva interface biomimetic to model fibrosis and local drug delivery
Bailly M
PLoS ONE 2020; 15: e0241569 (IGR: 21-4)

91819 Topical preservative-free ophthalmic treatments: an unmet clinical need
Mastropasqua L
Expert Opinion on Drug Delivery 2020; 0: 1-18 (IGR: 21-4)

91447 Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
Trakanwitthayarak S
Clinical Ophthalmology 2020; 14: 3109-3119 (IGR: 21-4)

91669 Topical Bimatoprost Insert for Primary Open-Angle Glaucoma and Ocular Hypertension Treatment - A Phase II Controlled Study
Nogueira JC
Current Drug Delivery 2020; 0: (IGR: 21-4)

91553 Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions
Hadžiabdić J
Pharmaceutics 2020; 13: (IGR: 21-4)

90873 Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1)
Goodkin ML
Ophthalmology 2020; 127: 1627-1641 (IGR: 21-4)

91266 Assessment of Corneal Epithelium Thickness in Glaucomatous Patients Undergoing Medical Treatment
Konstadinidou V
Journal of Glaucoma 2021; 30: 44-49 (IGR: 21-4)

91474 The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability
Boboridis KG
Expert Opinion on Drug Safety 2021; 0: 1-14 (IGR: 21-4)

91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Subias M
Biomaterials science 2020; 8: 6246-6260 (IGR: 21-4)

91846 Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure
Tan A
Acta Ophthalmologica 2021; 99: 376-382 (IGR: 21-4)

91260 Assessment of Ocular Surface Disease in Glaucoma Patients in Ghana
Akowuah PK
Journal of Glaucoma 2021; 30: 180-186 (IGR: 21-4)

91474 The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability
Holló G
Expert Opinion on Drug Safety 2021; 0: 1-14 (IGR: 21-4)

91846 Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure
Loftsson T
Acta Ophthalmologica 2021; 99: 376-382 (IGR: 21-4)

91669 Topical Bimatoprost Insert for Primary Open-Angle Glaucoma and Ocular Hypertension Treatment - A Phase II Controlled Study
Ferreira AJ
Current Drug Delivery 2020; 0: (IGR: 21-4)

91799 Novel Eye Drop Delivery Aid Improves Outcomes and Satisfaction
Rees JP
Ophthalmology. Glaucoma 2021; 0: (IGR: 21-4)

90873 Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1)
Guo Q
Ophthalmology 2020; 127: 1627-1641 (IGR: 21-4)

91819 Topical preservative-free ophthalmic treatments: an unmet clinical need
Posarelli C
Expert Opinion on Drug Delivery 2020; 0: 1-18 (IGR: 21-4)

91553 Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions
Vranić E
Pharmaceutics 2020; 13: (IGR: 21-4)

91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Polo V
Biomaterials science 2020; 8: 6246-6260 (IGR: 21-4)

91669 Topical Bimatoprost Insert for Primary Open-Angle Glaucoma and Ocular Hypertension Treatment - A Phase II Controlled Study
Faraco AAG
Current Drug Delivery 2020; 0: (IGR: 21-4)

91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Ruberte J
Biomaterials science 2020; 8: 6246-6260 (IGR: 21-4)

90873 Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1)
Zhang J
Ophthalmology 2020; 127: 1627-1641 (IGR: 21-4)

91474 The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability
García-Feijoo J
Expert Opinion on Drug Safety 2021; 0: 1-14 (IGR: 21-4)

91799 Novel Eye Drop Delivery Aid Improves Outcomes and Satisfaction
Jones EP
Ophthalmology. Glaucoma 2021; 0: (IGR: 21-4)

91846 Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure
Stefansson E
Acta Ophthalmologica 2021; 99: 376-382 (IGR: 21-4)

91474 The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability
Dutton GN
Expert Opinion on Drug Safety 2021; 0: 1-14 (IGR: 21-4)

91669 Topical Bimatoprost Insert for Primary Open-Angle Glaucoma and Ocular Hypertension Treatment - A Phase II Controlled Study
Foureaux G
Current Drug Delivery 2020; 0: (IGR: 21-4)

91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Ramirez T
Biomaterials science 2020; 8: 6246-6260 (IGR: 21-4)

91799 Novel Eye Drop Delivery Aid Improves Outcomes and Satisfaction
Kinast RM
Ophthalmology. Glaucoma 2021; 0: (IGR: 21-4)

90873 Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1)
Robinson MR
Ophthalmology 2020; 127: 1627-1641 (IGR: 21-4)

91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Vispe E
Biomaterials science 2020; 8: 6246-6260 (IGR: 21-4)

91474 The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability
Baudouin C
Expert Opinion on Drug Safety 2021; 0: 1-14 (IGR: 21-4)

90873 Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1)
Weinreb RN
Ophthalmology 2020; 127: 1627-1641 (IGR: 21-4)

91669 Topical Bimatoprost Insert for Primary Open-Angle Glaucoma and Ocular Hypertension Treatment - A Phase II Controlled Study
Cronemberger S
Current Drug Delivery 2020; 0: (IGR: 21-4)

90873 Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1)

Ophthalmology 2020; 127: 1627-1641 (IGR: 21-4)

91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Luna C; Mayoral JA; Garcia-Martin E
Biomaterials science 2020; 8: 6246-6260 (IGR: 21-4)

90851 Fasudil Loaded PLGA Microspheres as Potential Intravitreal Depot Formulation for Glaucoma Therapy
Mietzner R
Pharmaceutics 2020; 12: (IGR: 21-3)

89986 Potential Therapeutic Usage of Nanomedicine for Glaucoma Treatment
Kwon S
International Journal of Nanomedicine 2020; 15: 5745-5765 (IGR: 21-3)

90541 Nanoemulsion as a feasible and biocompatible carrier for ocular delivery of travoprost: Improved pharmacokinetic/pharmacodynamic properties
Ismail A
International Journal of Pharmaceutics 2020; 583: 119402 (IGR: 21-3)

90627 Effects of shell thickness of hollow poly(lactic acid) nanoparticles on sustained drug delivery for pharmacological treatment of glaucoma
Nguyen DD
Acta biomaterialia 2020; 111: 302-315 (IGR: 21-3)

90655 Numerical modeling of therapeutic lens drug delivery in the anterior human eye for the treatment of primary open-angle glaucoma
Bhandari A
Proceedings of the Institution of Mechanical Engineers. Part H, Journal of engineering in medicine 2020; 234: 942-954 (IGR: 21-3)

90725 Targeted Delivery of Cell Softening Micelles to Schlemm's Canal Endothelial Cells for Treatment of Glaucoma
Stack T
Small (Weinheim an der Bergstrasse, Germany) 2020; 16: e2004205 (IGR: 21-3)

90618 Self-assembled DNA nanoparticles loaded with travoprost for glaucoma-treatment
Schnichels S
Nanomedicine: Nanotechnology, Biology, and Medicine 2020; 29: 102260 (IGR: 21-3)

89876 Bimatoprost Implant: First Approval
Shirley M
Drugs and Aging 2020; 37: 457-462 (IGR: 21-3)

90570 Nanoscale Drug Delivery Systems for Glaucoma: Experimental and In Silico Advances
Sharma S
Current Topics in Medicinal Chemistry 2021; 21: 115-125 (IGR: 21-3)

90679 Ocular co-Delivery of Timolol and Brimonidine from a Self-Assembling Peptide Hydrogel for the Treatment of Glaucoma: In Vitro and Ex Vivo Evaluation
Taka E
Pharmaceuticals (Basel, Switzerland) 2020; 13: (IGR: 21-3)

90021 Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma
Kompella UB
Progress in Retinal and Eye Research 2020; 0: 100901 (IGR: 21-3)

90507 The protective effect of 3% diquafosol on meibomian gland morphology in glaucoma patients treated with prostaglandin analogs: a 12-month follow-up study
Guo Y
BMC Ophthalmology 2020; 20: 277 (IGR: 21-3)

90736 New antiglaucomatous agent for the treatment of open angle glaucoma: Polymeric inserts for drug release and in vitro and in vivo study
Cesar ALA
Journal of Biomedical Materials Research - Part A 2021; 109: 336-345 (IGR: 21-3)

90502 The Efficacy Between Conventional Lid Hygiene and Additional Thermal Pulsatile System in Meibomian Gland Dysfunction Patients Treated with Long-Term Anti-Glaucoma Medications in a Randomized Controlled Trial
Kasetsuwan N
Clinical Ophthalmology 2020; 14: 2891-2902 (IGR: 21-3)

90630 Mucoadhesive and responsive nanogels as carriers for sustainable delivery of timolol for glaucoma therapy
Cuggino JC
Materials science & engineering. C, Materials for biological applications 2021; 118: 111383 (IGR: 21-3)

90803 Micro-interaction of mucin tear film interface with particles: The inconsistency of pharmacodynamics and precorneal retention of ion-exchange, functionalized, Mt-embedded nano- and microparticles
Han X
Colloids and surfaces. B, Biointerfaces 2021; 197: 111355 (IGR: 21-3)

90661 Polypeptide and glycosaminoglycan polysaccharide as stabilizing polymers in nanocrystals for a safe ocular hypotensive effect
Donia M
International Journal of Biological Macromolecules 2020; 162: 1699-1710 (IGR: 21-3)

90459 Profiling ocular surface responses to preserved and non-preserved topical glaucoma medications: A 2-year randomized evaluation study
Mohammed I
Clinical and Experimental Ophthalmology 2020; 48: 973-982 (IGR: 21-3)

89989 Intractable Ocular Diseases and Treatment Progress
Zhang X
AAPS PharmSciTech 2020; 21: 236 (IGR: 21-3)

90627 Effects of shell thickness of hollow poly(lactic acid) nanoparticles on sustained drug delivery for pharmacological treatment of glaucoma
Nguyen DD
Acta biomaterialia 2020; 111: 302-315 (IGR: 21-3)

90672 Effect of aging on heat transfer, fluid flow and drug transport in anterior human eye: A computational study
Bhandari A
Journal of Controlled Release 2020; 328: 286-303 (IGR: 21-3)

90473 Effect of Long-Term Topical Antiglaucoma Medication Use on the Ocular Surface
Awe OO
Nigerian medical journal : journal of the Nigeria Medical Association 2020; 61: 184-188 (IGR: 21-3)

90252 Conjunctival structure of glaucomatous eyes treated with anti-glaucoma eye drops: a cross-sectional study using anterior segment optical coherence tomography
Gozawa M
BMC Ophthalmology 2020; 20: 244 (IGR: 21-3)

90459 Profiling ocular surface responses to preserved and non-preserved topical glaucoma medications: A 2-year randomized evaluation study
Kulkarni B
Clinical and Experimental Ophthalmology 2020; 48: 973-982 (IGR: 21-3)

90502 The Efficacy Between Conventional Lid Hygiene and Additional Thermal Pulsatile System in Meibomian Gland Dysfunction Patients Treated with Long-Term Anti-Glaucoma Medications in a Randomized Controlled Trial
Suwajanakorn D
Clinical Ophthalmology 2020; 14: 2891-2902 (IGR: 21-3)

90021 Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma
Hartman RR
Progress in Retinal and Eye Research 2020; 0: 100901 (IGR: 21-3)

90661 Polypeptide and glycosaminoglycan polysaccharide as stabilizing polymers in nanocrystals for a safe ocular hypotensive effect
Osman R
International Journal of Biological Macromolecules 2020; 162: 1699-1710 (IGR: 21-3)

89989 Intractable Ocular Diseases and Treatment Progress
Li S
AAPS PharmSciTech 2020; 21: 236 (IGR: 21-3)

90630 Mucoadhesive and responsive nanogels as carriers for sustainable delivery of timolol for glaucoma therapy
Tártara LI
Materials science & engineering. C, Materials for biological applications 2021; 118: 111383 (IGR: 21-3)

90627 Effects of shell thickness of hollow poly(lactic acid) nanoparticles on sustained drug delivery for pharmacological treatment of glaucoma
Luo LJ
Acta biomaterialia 2020; 111: 302-315 (IGR: 21-3)

90252 Conjunctival structure of glaucomatous eyes treated with anti-glaucoma eye drops: a cross-sectional study using anterior segment optical coherence tomography
Takamura Y
BMC Ophthalmology 2020; 20: 244 (IGR: 21-3)

90473 Effect of Long-Term Topical Antiglaucoma Medication Use on the Ocular Surface
Onakpoya OH
Nigerian medical journal : journal of the Nigeria Medical Association 2020; 61: 184-188 (IGR: 21-3)

90672 Effect of aging on heat transfer, fluid flow and drug transport in anterior human eye: A computational study
Bansal A
Journal of Controlled Release 2020; 328: 286-303 (IGR: 21-3)

90507 The protective effect of 3% diquafosol on meibomian gland morphology in glaucoma patients treated with prostaglandin analogs: a 12-month follow-up study
Ha JY
BMC Ophthalmology 2020; 20: 277 (IGR: 21-3)

90736 New antiglaucomatous agent for the treatment of open angle glaucoma: Polymeric inserts for drug release and in vitro and in vivo study
Navarro LC
Journal of Biomedical Materials Research - Part A 2021; 109: 336-345 (IGR: 21-3)

90851 Fasudil Loaded PLGA Microspheres as Potential Intravitreal Depot Formulation for Glaucoma Therapy
Kade C
Pharmaceutics 2020; 12: (IGR: 21-3)

90541 Nanoemulsion as a feasible and biocompatible carrier for ocular delivery of travoprost: Improved pharmacokinetic/pharmacodynamic properties
Nasr M
International Journal of Pharmaceutics 2020; 583: 119402 (IGR: 21-3)

90655 Numerical modeling of therapeutic lens drug delivery in the anterior human eye for the treatment of primary open-angle glaucoma
Bansal A
Proceedings of the Institution of Mechanical Engineers. Part H, Journal of engineering in medicine 2020; 234: 942-954 (IGR: 21-3)

90725 Targeted Delivery of Cell Softening Micelles to Schlemm's Canal Endothelial Cells for Treatment of Glaucoma
Vincent M
Small (Weinheim an der Bergstrasse, Germany) 2020; 16: e2004205 (IGR: 21-3)

90618 Self-assembled DNA nanoparticles loaded with travoprost for glaucoma-treatment
Hurst J
Nanomedicine: Nanotechnology, Biology, and Medicine 2020; 29: 102260 (IGR: 21-3)

89986 Potential Therapeutic Usage of Nanomedicine for Glaucoma Treatment
Kim SH
International Journal of Nanomedicine 2020; 15: 5745-5765 (IGR: 21-3)

90679 Ocular co-Delivery of Timolol and Brimonidine from a Self-Assembling Peptide Hydrogel for the Treatment of Glaucoma: In Vitro and Ex Vivo Evaluation
Karavasili C
Pharmaceuticals (Basel, Switzerland) 2020; 13: (IGR: 21-3)

90570 Nanoscale Drug Delivery Systems for Glaucoma: Experimental and In Silico Advances
Bhatia V
Current Topics in Medicinal Chemistry 2021; 21: 115-125 (IGR: 21-3)

90803 Micro-interaction of mucin tear film interface with particles: The inconsistency of pharmacodynamics and precorneal retention of ion-exchange, functionalized, Mt-embedded nano- and microparticles
Zhao Y
Colloids and surfaces. B, Biointerfaces 2021; 197: 111355 (IGR: 21-3)

90661 Polypeptide and glycosaminoglycan polysaccharide as stabilizing polymers in nanocrystals for a safe ocular hypotensive effect
Awad GAS
International Journal of Biological Macromolecules 2020; 162: 1699-1710 (IGR: 21-3)

90672 Effect of aging on heat transfer, fluid flow and drug transport in anterior human eye: A computational study
Sinha N
Journal of Controlled Release 2020; 328: 286-303 (IGR: 21-3)

90473 Effect of Long-Term Topical Antiglaucoma Medication Use on the Ocular Surface
Adeoye AO
Nigerian medical journal : journal of the Nigeria Medical Association 2020; 61: 184-188 (IGR: 21-3)

90655 Numerical modeling of therapeutic lens drug delivery in the anterior human eye for the treatment of primary open-angle glaucoma
Sinha N
Proceedings of the Institution of Mechanical Engineers. Part H, Journal of engineering in medicine 2020; 234: 942-954 (IGR: 21-3)

90851 Fasudil Loaded PLGA Microspheres as Potential Intravitreal Depot Formulation for Glaucoma Therapy
Froemel F
Pharmaceutics 2020; 12: (IGR: 21-3)

90672 Effect of aging on heat transfer, fluid flow and drug transport in anterior human eye: A computational study
Sinha N
Journal of Controlled Release 2020; 328: 286-303 (IGR: 21-3)

90618 Self-assembled DNA nanoparticles loaded with travoprost for glaucoma-treatment
de Vries JW
Nanomedicine: Nanotechnology, Biology, and Medicine 2020; 29: 102260 (IGR: 21-3)

89986 Potential Therapeutic Usage of Nanomedicine for Glaucoma Treatment
Khang D
International Journal of Nanomedicine 2020; 15: 5745-5765 (IGR: 21-3)

90507 The protective effect of 3% diquafosol on meibomian gland morphology in glaucoma patients treated with prostaglandin analogs: a 12-month follow-up study
Piao HL
BMC Ophthalmology 2020; 20: 277 (IGR: 21-3)

90630 Mucoadhesive and responsive nanogels as carriers for sustainable delivery of timolol for glaucoma therapy
Gugliotta LM
Materials science & engineering. C, Materials for biological applications 2021; 118: 111383 (IGR: 21-3)

90679 Ocular co-Delivery of Timolol and Brimonidine from a Self-Assembling Peptide Hydrogel for the Treatment of Glaucoma: In Vitro and Ex Vivo Evaluation
Bouropoulos N
Pharmaceuticals (Basel, Switzerland) 2020; 13: (IGR: 21-3)

90541 Nanoemulsion as a feasible and biocompatible carrier for ocular delivery of travoprost: Improved pharmacokinetic/pharmacodynamic properties
Sammour O
International Journal of Pharmaceutics 2020; 583: 119402 (IGR: 21-3)

90803 Micro-interaction of mucin tear film interface with particles: The inconsistency of pharmacodynamics and precorneal retention of ion-exchange, functionalized, Mt-embedded nano- and microparticles
Liu H
Colloids and surfaces. B, Biointerfaces 2021; 197: 111355 (IGR: 21-3)

90655 Numerical modeling of therapeutic lens drug delivery in the anterior human eye for the treatment of primary open-angle glaucoma
Sinha N
Proceedings of the Institution of Mechanical Engineers. Part H, Journal of engineering in medicine 2020; 234: 942-954 (IGR: 21-3)

90459 Profiling ocular surface responses to preserved and non-preserved topical glaucoma medications: A 2-year randomized evaluation study
Faraj LA
Clinical and Experimental Ophthalmology 2020; 48: 973-982 (IGR: 21-3)

90725 Targeted Delivery of Cell Softening Micelles to Schlemm's Canal Endothelial Cells for Treatment of Glaucoma
Vahabikashi A
Small (Weinheim an der Bergstrasse, Germany) 2020; 16: e2004205 (IGR: 21-3)

90627 Effects of shell thickness of hollow poly(lactic acid) nanoparticles on sustained drug delivery for pharmacological treatment of glaucoma
Lai JY
Acta biomaterialia 2020; 111: 302-315 (IGR: 21-3)

90252 Conjunctival structure of glaucomatous eyes treated with anti-glaucoma eye drops: a cross-sectional study using anterior segment optical coherence tomography
Iwasaki K
BMC Ophthalmology 2020; 20: 244 (IGR: 21-3)

90502 The Efficacy Between Conventional Lid Hygiene and Additional Thermal Pulsatile System in Meibomian Gland Dysfunction Patients Treated with Long-Term Anti-Glaucoma Medications in a Randomized Controlled Trial
Tantipat C
Clinical Ophthalmology 2020; 14: 2891-2902 (IGR: 21-3)

90736 New antiglaucomatous agent for the treatment of open angle glaucoma: Polymeric inserts for drug release and in vitro and in vivo study
Castilho RO
Journal of Biomedical Materials Research - Part A 2021; 109: 336-345 (IGR: 21-3)

90021 Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma
Patil MA
Progress in Retinal and Eye Research 2020; 0: 100901 (IGR: 21-3)

89989 Intractable Ocular Diseases and Treatment Progress
Tang Y
AAPS PharmSciTech 2020; 21: 236 (IGR: 21-3)

90803 Micro-interaction of mucin tear film interface with particles: The inconsistency of pharmacodynamics and precorneal retention of ion-exchange, functionalized, Mt-embedded nano- and microparticles
Li H
Colloids and surfaces. B, Biointerfaces 2021; 197: 111355 (IGR: 21-3)

90252 Conjunctival structure of glaucomatous eyes treated with anti-glaucoma eye drops: a cross-sectional study using anterior segment optical coherence tomography
Arimura S
BMC Ophthalmology 2020; 20: 244 (IGR: 21-3)

90459 Profiling ocular surface responses to preserved and non-preserved topical glaucoma medications: A 2-year randomized evaluation study
Abbas A
Clinical and Experimental Ophthalmology 2020; 48: 973-982 (IGR: 21-3)

90502 The Efficacy Between Conventional Lid Hygiene and Additional Thermal Pulsatile System in Meibomian Gland Dysfunction Patients Treated with Long-Term Anti-Glaucoma Medications in a Randomized Controlled Trial
Reinprayoon U
Clinical Ophthalmology 2020; 14: 2891-2902 (IGR: 21-3)

90661 Polypeptide and glycosaminoglycan polysaccharide as stabilizing polymers in nanocrystals for a safe ocular hypotensive effect
Mortada N
International Journal of Biological Macromolecules 2020; 162: 1699-1710 (IGR: 21-3)

90851 Fasudil Loaded PLGA Microspheres as Potential Intravitreal Depot Formulation for Glaucoma Therapy
Pauly D
Pharmaceutics 2020; 12: (IGR: 21-3)

90725 Targeted Delivery of Cell Softening Micelles to Schlemm's Canal Endothelial Cells for Treatment of Glaucoma
Li G
Small (Weinheim an der Bergstrasse, Germany) 2020; 16: e2004205 (IGR: 21-3)

89989 Intractable Ocular Diseases and Treatment Progress
Guo Y
AAPS PharmSciTech 2020; 21: 236 (IGR: 21-3)

90630 Mucoadhesive and responsive nanogels as carriers for sustainable delivery of timolol for glaucoma therapy
Palma SD
Materials science & engineering. C, Materials for biological applications 2021; 118: 111383 (IGR: 21-3)

89986 Potential Therapeutic Usage of Nanomedicine for Glaucoma Treatment
Lee JY
International Journal of Nanomedicine 2020; 15: 5745-5765 (IGR: 21-3)

90679 Ocular co-Delivery of Timolol and Brimonidine from a Self-Assembling Peptide Hydrogel for the Treatment of Glaucoma: In Vitro and Ex Vivo Evaluation
Moschakis T
Pharmaceuticals (Basel, Switzerland) 2020; 13: (IGR: 21-3)

90507 The protective effect of 3% diquafosol on meibomian gland morphology in glaucoma patients treated with prostaglandin analogs: a 12-month follow-up study
Sung MS
BMC Ophthalmology 2020; 20: 277 (IGR: 21-3)

90736 New antiglaucomatous agent for the treatment of open angle glaucoma: Polymeric inserts for drug release and in vitro and in vivo study
Goulart GAC
Journal of Biomedical Materials Research - Part A 2021; 109: 336-345 (IGR: 21-3)

90618 Self-assembled DNA nanoparticles loaded with travoprost for glaucoma-treatment
Ullah S
Nanomedicine: Nanotechnology, Biology, and Medicine 2020; 29: 102260 (IGR: 21-3)

90736 New antiglaucomatous agent for the treatment of open angle glaucoma: Polymeric inserts for drug release and in vitro and in vivo study
Foureaux G
Journal of Biomedical Materials Research - Part A 2021; 109: 336-345 (IGR: 21-3)

90618 Self-assembled DNA nanoparticles loaded with travoprost for glaucoma-treatment
Gruszka A
Nanomedicine: Nanotechnology, Biology, and Medicine 2020; 29: 102260 (IGR: 21-3)

90459 Profiling ocular surface responses to preserved and non-preserved topical glaucoma medications: A 2-year randomized evaluation study
Dua HS
Clinical and Experimental Ophthalmology 2020; 48: 973-982 (IGR: 21-3)

90507 The protective effect of 3% diquafosol on meibomian gland morphology in glaucoma patients treated with prostaglandin analogs: a 12-month follow-up study
Park SW
BMC Ophthalmology 2020; 20: 277 (IGR: 21-3)

90803 Micro-interaction of mucin tear film interface with particles: The inconsistency of pharmacodynamics and precorneal retention of ion-exchange, functionalized, Mt-embedded nano- and microparticles
Liu S
Colloids and surfaces. B, Biointerfaces 2021; 197: 111355 (IGR: 21-3)

90252 Conjunctival structure of glaucomatous eyes treated with anti-glaucoma eye drops: a cross-sectional study using anterior segment optical coherence tomography
Inatani M
BMC Ophthalmology 2020; 20: 244 (IGR: 21-3)

89989 Intractable Ocular Diseases and Treatment Progress
Gao S
AAPS PharmSciTech 2020; 21: 236 (IGR: 21-3)

90679 Ocular co-Delivery of Timolol and Brimonidine from a Self-Assembling Peptide Hydrogel for the Treatment of Glaucoma: In Vitro and Ex Vivo Evaluation
Andreadis DDD
Pharmaceuticals (Basel, Switzerland) 2020; 13: (IGR: 21-3)

90851 Fasudil Loaded PLGA Microspheres as Potential Intravitreal Depot Formulation for Glaucoma Therapy
Stamer WD
Pharmaceutics 2020; 12: (IGR: 21-3)

90725 Targeted Delivery of Cell Softening Micelles to Schlemm's Canal Endothelial Cells for Treatment of Glaucoma
Perkumas KM
Small (Weinheim an der Bergstrasse, Germany) 2020; 16: e2004205 (IGR: 21-3)

90630 Mucoadhesive and responsive nanogels as carriers for sustainable delivery of timolol for glaucoma therapy
Alvarez Igarzabal CI
Materials science & engineering. C, Materials for biological applications 2021; 118: 111383 (IGR: 21-3)

90679 Ocular co-Delivery of Timolol and Brimonidine from a Self-Assembling Peptide Hydrogel for the Treatment of Glaucoma: In Vitro and Ex Vivo Evaluation
Zacharis CKK
Pharmaceuticals (Basel, Switzerland) 2020; 13: (IGR: 21-3)

90851 Fasudil Loaded PLGA Microspheres as Potential Intravitreal Depot Formulation for Glaucoma Therapy
Ohlmann A
Pharmaceutics 2020; 12: (IGR: 21-3)

90725 Targeted Delivery of Cell Softening Micelles to Schlemm's Canal Endothelial Cells for Treatment of Glaucoma
Stamer WD
Small (Weinheim an der Bergstrasse, Germany) 2020; 16: e2004205 (IGR: 21-3)

90736 New antiglaucomatous agent for the treatment of open angle glaucoma: Polymeric inserts for drug release and in vitro and in vivo study
Ferreira AJ
Journal of Biomedical Materials Research - Part A 2021; 109: 336-345 (IGR: 21-3)

90618 Self-assembled DNA nanoparticles loaded with travoprost for glaucoma-treatment
Kwak M
Nanomedicine: Nanotechnology, Biology, and Medicine 2020; 29: 102260 (IGR: 21-3)

90803 Micro-interaction of mucin tear film interface with particles: The inconsistency of pharmacodynamics and precorneal retention of ion-exchange, functionalized, Mt-embedded nano- and microparticles
Rupenthal ID
Colloids and surfaces. B, Biointerfaces 2021; 197: 111355 (IGR: 21-3)

90459 Profiling ocular surface responses to preserved and non-preserved topical glaucoma medications: A 2-year randomized evaluation study
King AJ
Clinical and Experimental Ophthalmology 2020; 48: 973-982 (IGR: 21-3)

90803 Micro-interaction of mucin tear film interface with particles: The inconsistency of pharmacodynamics and precorneal retention of ion-exchange, functionalized, Mt-embedded nano- and microparticles
Yang F
Colloids and surfaces. B, Biointerfaces 2021; 197: 111355 (IGR: 21-3)

90851 Fasudil Loaded PLGA Microspheres as Potential Intravitreal Depot Formulation for Glaucoma Therapy
Wegener J
Pharmaceutics 2020; 12: (IGR: 21-3)

90679 Ocular co-Delivery of Timolol and Brimonidine from a Self-Assembling Peptide Hydrogel for the Treatment of Glaucoma: In Vitro and Ex Vivo Evaluation
Fatouros DGG
Pharmaceuticals (Basel, Switzerland) 2020; 13: (IGR: 21-3)

90618 Self-assembled DNA nanoparticles loaded with travoprost for glaucoma-treatment
Löscher M
Nanomedicine: Nanotechnology, Biology, and Medicine 2020; 29: 102260 (IGR: 21-3)

90736 New antiglaucomatous agent for the treatment of open angle glaucoma: Polymeric inserts for drug release and in vitro and in vivo study
Cronemberger S
Journal of Biomedical Materials Research - Part A 2021; 109: 336-345 (IGR: 21-3)

90725 Targeted Delivery of Cell Softening Micelles to Schlemm's Canal Endothelial Cells for Treatment of Glaucoma
Johnson M
Small (Weinheim an der Bergstrasse, Germany) 2020; 16: e2004205 (IGR: 21-3)

90736 New antiglaucomatous agent for the treatment of open angle glaucoma: Polymeric inserts for drug release and in vitro and in vivo study
Gomes Faraco AA
Journal of Biomedical Materials Research - Part A 2021; 109: 336-345 (IGR: 21-3)

90851 Fasudil Loaded PLGA Microspheres as Potential Intravitreal Depot Formulation for Glaucoma Therapy
Fuchshofer R
Pharmaceutics 2020; 12: (IGR: 21-3)

90725 Targeted Delivery of Cell Softening Micelles to Schlemm's Canal Endothelial Cells for Treatment of Glaucoma
Scott E
Small (Weinheim an der Bergstrasse, Germany) 2020; 16: e2004205 (IGR: 21-3)

90618 Self-assembled DNA nanoparticles loaded with travoprost for glaucoma-treatment
Dammeier S
Nanomedicine: Nanotechnology, Biology, and Medicine 2020; 29: 102260 (IGR: 21-3)

90803 Micro-interaction of mucin tear film interface with particles: The inconsistency of pharmacodynamics and precorneal retention of ion-exchange, functionalized, Mt-embedded nano- and microparticles
Lv Z; Chen Y
Colloids and surfaces. B, Biointerfaces 2021; 197: 111355 (IGR: 21-3)

90851 Fasudil Loaded PLGA Microspheres as Potential Intravitreal Depot Formulation for Glaucoma Therapy
Breunig M
Pharmaceutics 2020; 12: (IGR: 21-3)

90618 Self-assembled DNA nanoparticles loaded with travoprost for glaucoma-treatment
Bartz-Schmidt KU
Nanomedicine: Nanotechnology, Biology, and Medicine 2020; 29: 102260 (IGR: 21-3)

90803 Micro-interaction of mucin tear film interface with particles: The inconsistency of pharmacodynamics and precorneal retention of ion-exchange, functionalized, Mt-embedded nano- and microparticles
Zang L
Colloids and surfaces. B, Biointerfaces 2021; 197: 111355 (IGR: 21-3)

90618 Self-assembled DNA nanoparticles loaded with travoprost for glaucoma-treatment
Spitzer MS; Herrmann A
Nanomedicine: Nanotechnology, Biology, and Medicine 2020; 29: 102260 (IGR: 21-3)

90803 Micro-interaction of mucin tear film interface with particles: The inconsistency of pharmacodynamics and precorneal retention of ion-exchange, functionalized, Mt-embedded nano- and microparticles
Li W; Ping Q; Tao Q; Hou D
Colloids and surfaces. B, Biointerfaces 2021; 197: 111355 (IGR: 21-3)

86753 Micelles: Promising Ocular Drug Carriers for Anterior and Posterior Segment Diseases
Durgun ME
Journal of Ocular Pharmacology and Therapeutics 2020; 36: 323-341 (IGR: 21-2)

86432 Reduction of intraocular pressure using timolol orally dissolving strips in the treatment of induced primary open-angle glaucoma in rabbits
El-Feky YA
Journal of Pharmacy and Pharmacology 2020; 72: 682-698 (IGR: 21-2)

86722 Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbits
Roy Chowdhury U
PLoS ONE 2020; 15: e0231841 (IGR: 21-2)

86651 Sustained subconjunctival delivery of cyclosporine A using thermogelling polymers for glaucoma filtration surgery
Sun J
Journal of materials chemistry. B 2017; 5: 6400-6411 (IGR: 21-2)

86685 Latanoprost niosomes as a sustained release ocular delivery system for the management of glaucoma
Fathalla D
Drug Development and Industrial Pharmacy 2020; 46: 806-813 (IGR: 21-2)

86650 Gelatin-functionalized mesoporous silica nanoparticles with sustained release properties for intracameral pharmacotherapy of glaucoma
Liao YT
Journal of materials chemistry. B 2017; 5: 7008-7013 (IGR: 21-2)

86433 Dually functional hollow ceria nanoparticle platform for intraocular drug delivery: A push beyond the limits of static and dynamic ocular barriers toward glaucoma therapy
Luo LJ
Biomaterials 2020; 243: 119961 (IGR: 21-2)

86844 Incorporation of ion exchange functionalized-montmorillonite into solid lipid nanoparticles with low irritation enhances drug bioavailability for glaucoma treatment
Liu S
Drug Delivery 2020; 27: 652-661 (IGR: 21-2)

86715 Corneal damage and its recovery after instillation of preservative-free versus preserved latanoprost eye drops
Inoue D
Cutaneous and Ocular Toxicology 2020; 39: 158-164 (IGR: 21-2)

86080 Continuous anti-glaucoma drug therapy as a risk factor of dry eye
Erichev VP
Vestnik Oftalmologii 2019; 135: 117-123 (IGR: 21-2)

86156 Efficacy and safety evaluation of benzalkonium chloride preserved eye-drops compared with alternatively preserved and preservative-free eye-drops in the treatment of glaucoma: a systematic review and meta-analysis
Hedengran A
British Journal of Ophthalmology 2020; 104: 1512-1518 (IGR: 21-2)

86339 Co-delivery of brinzolamide and miRNA-124 by biodegradable nanoparticles as a strategy for glaucoma therapy
Li T
Drug Delivery 2020; 27: 410-421 (IGR: 21-2)

86078 The effect of preservative-free treatment of primary open-angle glaucoma on the state of ocular surface in combination therapy (intermediate results)
Dorofeev DA
Vestnik Oftalmologii 2019; 135: 52-59 (IGR: 21-2)

86592 Gelatin Nanoparticles-HPMC Hybrid System for Effective Ocular Topical Administration of Antihypertensive Agents
Esteban-Pérez S
Pharmaceutics 2020; 12: (IGR: 21-2)

86597 Preservative-free versus preserved glaucoma eye drops and occurrence of glaucoma surgery. A retrospective study based on the French national health insurance information system, 2008-2016
Chamard C
Acta Ophthalmologica 2020; 98: e876-e881 (IGR: 21-2)

86199 Lipid Nanoparticles as Carriers for the Treatment of Neurodegeneration Associated with Alzheimer's Disease and Glaucoma: Present and Future Challenges
López ES
Current Pharmaceutical Design 2020; 26: 1235-1250 (IGR: 21-2)

86221 Tear Meniscus Imaging by Anterior Segment-Optical Coherence Tomography in Medically Controlled Glaucoma
Agnifili L
Journal of Glaucoma 2020; 29: 374-380 (IGR: 21-2)

86682 Factors Predetermining Increased Aqueous Humour Flare in Long-Term Glaucoma Treatment
Pakuliene G
Journal of Ophthalmology 2020; 2020: 7345687 (IGR: 21-2)

86724 Progress on ocular siRNA gene-silencing therapy and drug delivery systems
Jiang J
Fundamental and Clinical Pharmacology 2021; 35: 4-24 (IGR: 21-2)

86592 Gelatin Nanoparticles-HPMC Hybrid System for Effective Ocular Topical Administration of Antihypertensive Agents
Andrés-Guerrero V
Pharmaceutics 2020; 12: (IGR: 21-2)

86433 Dually functional hollow ceria nanoparticle platform for intraocular drug delivery: A push beyond the limits of static and dynamic ocular barriers toward glaucoma therapy
Nguyen DD
Biomaterials 2020; 243: 119961 (IGR: 21-2)

86650 Gelatin-functionalized mesoporous silica nanoparticles with sustained release properties for intracameral pharmacotherapy of glaucoma
Lee CH
Journal of materials chemistry. B 2017; 5: 7008-7013 (IGR: 21-2)

86221 Tear Meniscus Imaging by Anterior Segment-Optical Coherence Tomography in Medically Controlled Glaucoma
Brescia L
Journal of Glaucoma 2020; 29: 374-380 (IGR: 21-2)

86432 Reduction of intraocular pressure using timolol orally dissolving strips in the treatment of induced primary open-angle glaucoma in rabbits
Mostafa DA
Journal of Pharmacy and Pharmacology 2020; 72: 682-698 (IGR: 21-2)

86080 Continuous anti-glaucoma drug therapy as a risk factor of dry eye
Petrov SY
Vestnik Oftalmologii 2019; 135: 117-123 (IGR: 21-2)

86339 Co-delivery of brinzolamide and miRNA-124 by biodegradable nanoparticles as a strategy for glaucoma therapy
Wang Y
Drug Delivery 2020; 27: 410-421 (IGR: 21-2)

86080 Continuous anti-glaucoma drug therapy as a risk factor of dry eye
Petrov SY
Vestnik Oftalmologii 2019; 135: 117-123 (IGR: 21-2)

86724 Progress on ocular siRNA gene-silencing therapy and drug delivery systems
Zhang X
Fundamental and Clinical Pharmacology 2021; 35: 4-24 (IGR: 21-2)

86597 Preservative-free versus preserved glaucoma eye drops and occurrence of glaucoma surgery. A retrospective study based on the French national health insurance information system, 2008-2016
Larrieu S
Acta Ophthalmologica 2020; 98: e876-e881 (IGR: 21-2)

86199 Lipid Nanoparticles as Carriers for the Treatment of Neurodegeneration Associated with Alzheimer's Disease and Glaucoma: Present and Future Challenges
Machado ALL
Current Pharmaceutical Design 2020; 26: 1235-1250 (IGR: 21-2)

86651 Sustained subconjunctival delivery of cyclosporine A using thermogelling polymers for glaucoma filtration surgery
Liu X
Journal of materials chemistry. B 2017; 5: 6400-6411 (IGR: 21-2)

86682 Factors Predetermining Increased Aqueous Humour Flare in Long-Term Glaucoma Treatment
Kuzmiene L
Journal of Ophthalmology 2020; 2020: 7345687 (IGR: 21-2)

86722 Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbits
Kudgus RA
PLoS ONE 2020; 15: e0231841 (IGR: 21-2)

86080 Continuous anti-glaucoma drug therapy as a risk factor of dry eye
Petrov SY
Vestnik Oftalmologii 2019; 135: 117-123 (IGR: 21-2)

86753 Micelles: Promising Ocular Drug Carriers for Anterior and Posterior Segment Diseases
Güngör S
Journal of Ocular Pharmacology and Therapeutics 2020; 36: 323-341 (IGR: 21-2)

86844 Incorporation of ion exchange functionalized-montmorillonite into solid lipid nanoparticles with low irritation enhances drug bioavailability for glaucoma treatment
Han X
Drug Delivery 2020; 27: 652-661 (IGR: 21-2)

86715 Corneal damage and its recovery after instillation of preservative-free versus preserved latanoprost eye drops
Mohamed YH
Cutaneous and Ocular Toxicology 2020; 39: 158-164 (IGR: 21-2)

86433 Dually functional hollow ceria nanoparticle platform for intraocular drug delivery: A push beyond the limits of static and dynamic ocular barriers toward glaucoma therapy
Nguyen DD
Biomaterials 2020; 243: 119961 (IGR: 21-2)

86156 Efficacy and safety evaluation of benzalkonium chloride preserved eye-drops compared with alternatively preserved and preservative-free eye-drops in the treatment of glaucoma: a systematic review and meta-analysis
Steensberg AT
British Journal of Ophthalmology 2020; 104: 1512-1518 (IGR: 21-2)

86685 Latanoprost niosomes as a sustained release ocular delivery system for the management of glaucoma
Fouad EA
Drug Development and Industrial Pharmacy 2020; 46: 806-813 (IGR: 21-2)

86078 The effect of preservative-free treatment of primary open-angle glaucoma on the state of ocular surface in combination therapy (intermediate results)
Tur EV
Vestnik Oftalmologii 2019; 135: 52-59 (IGR: 21-2)

86080 Continuous anti-glaucoma drug therapy as a risk factor of dry eye
Petrov SY
Vestnik Oftalmologii 2019; 135: 117-123 (IGR: 21-2)

86722 Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbits
Rinkoski TA
PLoS ONE 2020; 15: e0231841 (IGR: 21-2)

86682 Factors Predetermining Increased Aqueous Humour Flare in Long-Term Glaucoma Treatment
Januleviciene I
Journal of Ophthalmology 2020; 2020: 7345687 (IGR: 21-2)

86715 Corneal damage and its recovery after instillation of preservative-free versus preserved latanoprost eye drops
Uematsu M
Cutaneous and Ocular Toxicology 2020; 39: 158-164 (IGR: 21-2)

86080 Continuous anti-glaucoma drug therapy as a risk factor of dry eye
Volzhanin AV
Vestnik Oftalmologii 2019; 135: 117-123 (IGR: 21-2)

86339 Co-delivery of brinzolamide and miRNA-124 by biodegradable nanoparticles as a strategy for glaucoma therapy
Chen J
Drug Delivery 2020; 27: 410-421 (IGR: 21-2)

86080 Continuous anti-glaucoma drug therapy as a risk factor of dry eye
Volzhanin AV
Vestnik Oftalmologii 2019; 135: 117-123 (IGR: 21-2)

86753 Micelles: Promising Ocular Drug Carriers for Anterior and Posterior Segment Diseases
Özsoy Y
Journal of Ocular Pharmacology and Therapeutics 2020; 36: 323-341 (IGR: 21-2)

86432 Reduction of intraocular pressure using timolol orally dissolving strips in the treatment of induced primary open-angle glaucoma in rabbits
Al-Sawahli MM
Journal of Pharmacy and Pharmacology 2020; 72: 682-698 (IGR: 21-2)

86592 Gelatin Nanoparticles-HPMC Hybrid System for Effective Ocular Topical Administration of Antihypertensive Agents
López-Cano JJ
Pharmaceutics 2020; 12: (IGR: 21-2)

86156 Efficacy and safety evaluation of benzalkonium chloride preserved eye-drops compared with alternatively preserved and preservative-free eye-drops in the treatment of glaucoma: a systematic review and meta-analysis
Virgili G
British Journal of Ophthalmology 2020; 104: 1512-1518 (IGR: 21-2)

86080 Continuous anti-glaucoma drug therapy as a risk factor of dry eye
Volzhanin AV
Vestnik Oftalmologii 2019; 135: 117-123 (IGR: 21-2)

86724 Progress on ocular siRNA gene-silencing therapy and drug delivery systems
Tang Y
Fundamental and Clinical Pharmacology 2021; 35: 4-24 (IGR: 21-2)

86597 Preservative-free versus preserved glaucoma eye drops and occurrence of glaucoma surgery. A retrospective study based on the French national health insurance information system, 2008-2016
Baudouin C
Acta Ophthalmologica 2020; 98: e876-e881 (IGR: 21-2)

86650 Gelatin-functionalized mesoporous silica nanoparticles with sustained release properties for intracameral pharmacotherapy of glaucoma
Chen ST
Journal of materials chemistry. B 2017; 5: 7008-7013 (IGR: 21-2)

86685 Latanoprost niosomes as a sustained release ocular delivery system for the management of glaucoma
Soliman GM
Drug Development and Industrial Pharmacy 2020; 46: 806-813 (IGR: 21-2)

86433 Dually functional hollow ceria nanoparticle platform for intraocular drug delivery: A push beyond the limits of static and dynamic ocular barriers toward glaucoma therapy
Lai JY
Biomaterials 2020; 243: 119961 (IGR: 21-2)

86078 The effect of preservative-free treatment of primary open-angle glaucoma on the state of ocular surface in combination therapy (intermediate results)
Vizgalova LO
Vestnik Oftalmologii 2019; 135: 52-59 (IGR: 21-2)

86080 Continuous anti-glaucoma drug therapy as a risk factor of dry eye
Volzhanin AV
Vestnik Oftalmologii 2019; 135: 117-123 (IGR: 21-2)

86651 Sustained subconjunctival delivery of cyclosporine A using thermogelling polymers for glaucoma filtration surgery
Lei Y
Journal of materials chemistry. B 2017; 5: 6400-6411 (IGR: 21-2)

86844 Incorporation of ion exchange functionalized-montmorillonite into solid lipid nanoparticles with low irritation enhances drug bioavailability for glaucoma treatment
Liu H
Drug Delivery 2020; 27: 652-661 (IGR: 21-2)

86199 Lipid Nanoparticles as Carriers for the Treatment of Neurodegeneration Associated with Alzheimer's Disease and Glaucoma: Present and Future Challenges
Vidal LB
Current Pharmaceutical Design 2020; 26: 1235-1250 (IGR: 21-2)

86221 Tear Meniscus Imaging by Anterior Segment-Optical Coherence Tomography in Medically Controlled Glaucoma
Scatena B
Journal of Glaucoma 2020; 29: 374-380 (IGR: 21-2)

86080 Continuous anti-glaucoma drug therapy as a risk factor of dry eye
Ghazaryan SA
Vestnik Oftalmologii 2019; 135: 117-123 (IGR: 21-2)

86199 Lipid Nanoparticles as Carriers for the Treatment of Neurodegeneration Associated with Alzheimer's Disease and Glaucoma: Present and Future Challenges
González-Pizarro R
Current Pharmaceutical Design 2020; 26: 1235-1250 (IGR: 21-2)

86078 The effect of preservative-free treatment of primary open-angle glaucoma on the state of ocular surface in combination therapy (intermediate results)
Tryapitsin ID
Vestnik Oftalmologii 2019; 135: 52-59 (IGR: 21-2)

86724 Progress on ocular siRNA gene-silencing therapy and drug delivery systems
Li S
Fundamental and Clinical Pharmacology 2021; 35: 4-24 (IGR: 21-2)

86592 Gelatin Nanoparticles-HPMC Hybrid System for Effective Ocular Topical Administration of Antihypertensive Agents
Molina-Martínez I
Pharmaceutics 2020; 12: (IGR: 21-2)

86844 Incorporation of ion exchange functionalized-montmorillonite into solid lipid nanoparticles with low irritation enhances drug bioavailability for glaucoma treatment
Zhao Y
Drug Delivery 2020; 27: 652-661 (IGR: 21-2)

86221 Tear Meniscus Imaging by Anterior Segment-Optical Coherence Tomography in Medically Controlled Glaucoma
Oddone F
Journal of Glaucoma 2020; 29: 374-380 (IGR: 21-2)

86715 Corneal damage and its recovery after instillation of preservative-free versus preserved latanoprost eye drops
Kitaoka T
Cutaneous and Ocular Toxicology 2020; 39: 158-164 (IGR: 21-2)

86722 Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbits
Holman BH
PLoS ONE 2020; 15: e0231841 (IGR: 21-2)

86651 Sustained subconjunctival delivery of cyclosporine A using thermogelling polymers for glaucoma filtration surgery
Tang M
Journal of materials chemistry. B 2017; 5: 6400-6411 (IGR: 21-2)

86432 Reduction of intraocular pressure using timolol orally dissolving strips in the treatment of induced primary open-angle glaucoma in rabbits
El-Telbany RFA
Journal of Pharmacy and Pharmacology 2020; 72: 682-698 (IGR: 21-2)

86156 Efficacy and safety evaluation of benzalkonium chloride preserved eye-drops compared with alternatively preserved and preservative-free eye-drops in the treatment of glaucoma: a systematic review and meta-analysis
Azuara-Blanco A
British Journal of Ophthalmology 2020; 104: 1512-1518 (IGR: 21-2)

86339 Co-delivery of brinzolamide and miRNA-124 by biodegradable nanoparticles as a strategy for glaucoma therapy
Gao X
Drug Delivery 2020; 27: 410-421 (IGR: 21-2)

86597 Preservative-free versus preserved glaucoma eye drops and occurrence of glaucoma surgery. A retrospective study based on the French national health insurance information system, 2008-2016
Bron A
Acta Ophthalmologica 2020; 98: e876-e881 (IGR: 21-2)

86650 Gelatin-functionalized mesoporous silica nanoparticles with sustained release properties for intracameral pharmacotherapy of glaucoma
Lai JY; Wu KC
Journal of materials chemistry. B 2017; 5: 7008-7013 (IGR: 21-2)

86156 Efficacy and safety evaluation of benzalkonium chloride preserved eye-drops compared with alternatively preserved and preservative-free eye-drops in the treatment of glaucoma: a systematic review and meta-analysis
Kolko M
British Journal of Ophthalmology 2020; 104: 1512-1518 (IGR: 21-2)

86199 Lipid Nanoparticles as Carriers for the Treatment of Neurodegeneration Associated with Alzheimer's Disease and Glaucoma: Present and Future Challenges
Silva AD
Current Pharmaceutical Design 2020; 26: 1235-1250 (IGR: 21-2)

86597 Preservative-free versus preserved glaucoma eye drops and occurrence of glaucoma surgery. A retrospective study based on the French national health insurance information system, 2008-2016
Villain M
Acta Ophthalmologica 2020; 98: e876-e881 (IGR: 21-2)

86651 Sustained subconjunctival delivery of cyclosporine A using thermogelling polymers for glaucoma filtration surgery
Dai Z
Journal of materials chemistry. B 2017; 5: 6400-6411 (IGR: 21-2)

86078 The effect of preservative-free treatment of primary open-angle glaucoma on the state of ocular surface in combination therapy (intermediate results)
Ciganov AZ
Vestnik Oftalmologii 2019; 135: 52-59 (IGR: 21-2)

86221 Tear Meniscus Imaging by Anterior Segment-Optical Coherence Tomography in Medically Controlled Glaucoma
Figus M
Journal of Glaucoma 2020; 29: 374-380 (IGR: 21-2)

86339 Co-delivery of brinzolamide and miRNA-124 by biodegradable nanoparticles as a strategy for glaucoma therapy
Pan S
Drug Delivery 2020; 27: 410-421 (IGR: 21-2)

86592 Gelatin Nanoparticles-HPMC Hybrid System for Effective Ocular Topical Administration of Antihypertensive Agents
Herrero-Vanrell R
Pharmaceutics 2020; 12: (IGR: 21-2)

86844 Incorporation of ion exchange functionalized-montmorillonite into solid lipid nanoparticles with low irritation enhances drug bioavailability for glaucoma treatment
Li H
Drug Delivery 2020; 27: 652-661 (IGR: 21-2)

86722 Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbits
Bahler CK
PLoS ONE 2020; 15: e0231841 (IGR: 21-2)

86724 Progress on ocular siRNA gene-silencing therapy and drug delivery systems
Chen J
Fundamental and Clinical Pharmacology 2021; 35: 4-24 (IGR: 21-2)

86432 Reduction of intraocular pressure using timolol orally dissolving strips in the treatment of induced primary open-angle glaucoma in rabbits
Zakaria S
Journal of Pharmacy and Pharmacology 2020; 72: 682-698 (IGR: 21-2)

86597 Preservative-free versus preserved glaucoma eye drops and occurrence of glaucoma surgery. A retrospective study based on the French national health insurance information system, 2008-2016
Daien V
Acta Ophthalmologica 2020; 98: e876-e881 (IGR: 21-2)

86339 Co-delivery of brinzolamide and miRNA-124 by biodegradable nanoparticles as a strategy for glaucoma therapy
Su Y
Drug Delivery 2020; 27: 410-421 (IGR: 21-2)

86651 Sustained subconjunctival delivery of cyclosporine A using thermogelling polymers for glaucoma filtration surgery
Yang X
Journal of materials chemistry. B 2017; 5: 6400-6411 (IGR: 21-2)

86432 Reduction of intraocular pressure using timolol orally dissolving strips in the treatment of induced primary open-angle glaucoma in rabbits
Fayez AM
Journal of Pharmacy and Pharmacology 2020; 72: 682-698 (IGR: 21-2)

86722 Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbits
Hann CR
PLoS ONE 2020; 15: e0231841 (IGR: 21-2)

86592 Gelatin Nanoparticles-HPMC Hybrid System for Effective Ocular Topical Administration of Antihypertensive Agents
Bravo-Osuna I
Pharmaceutics 2020; 12: (IGR: 21-2)

86199 Lipid Nanoparticles as Carriers for the Treatment of Neurodegeneration Associated with Alzheimer's Disease and Glaucoma: Present and Future Challenges
Souto EB
Current Pharmaceutical Design 2020; 26: 1235-1250 (IGR: 21-2)

86221 Tear Meniscus Imaging by Anterior Segment-Optical Coherence Tomography in Medically Controlled Glaucoma
Perna F
Journal of Glaucoma 2020; 29: 374-380 (IGR: 21-2)

86844 Incorporation of ion exchange functionalized-montmorillonite into solid lipid nanoparticles with low irritation enhances drug bioavailability for glaucoma treatment
D Rupenthal I
Drug Delivery 2020; 27: 652-661 (IGR: 21-2)

86221 Tear Meniscus Imaging by Anterior Segment-Optical Coherence Tomography in Medically Controlled Glaucoma
Doronzo E
Journal of Glaucoma 2020; 29: 374-380 (IGR: 21-2)

86722 Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbits
Reid JM
PLoS ONE 2020; 15: e0231841 (IGR: 21-2)

86844 Incorporation of ion exchange functionalized-montmorillonite into solid lipid nanoparticles with low irritation enhances drug bioavailability for glaucoma treatment
Lv Z
Drug Delivery 2020; 27: 652-661 (IGR: 21-2)

86651 Sustained subconjunctival delivery of cyclosporine A using thermogelling polymers for glaucoma filtration surgery
Yu X
Journal of materials chemistry. B 2017; 5: 6400-6411 (IGR: 21-2)

86339 Co-delivery of brinzolamide and miRNA-124 by biodegradable nanoparticles as a strategy for glaucoma therapy
Zhou X
Drug Delivery 2020; 27: 410-421 (IGR: 21-2)

86432 Reduction of intraocular pressure using timolol orally dissolving strips in the treatment of induced primary open-angle glaucoma in rabbits
Ahmed KA
Journal of Pharmacy and Pharmacology 2020; 72: 682-698 (IGR: 21-2)

86844 Incorporation of ion exchange functionalized-montmorillonite into solid lipid nanoparticles with low irritation enhances drug bioavailability for glaucoma treatment
Chen Y
Drug Delivery 2020; 27: 652-661 (IGR: 21-2)

86221 Tear Meniscus Imaging by Anterior Segment-Optical Coherence Tomography in Medically Controlled Glaucoma
D'Ugo E
Journal of Glaucoma 2020; 29: 374-380 (IGR: 21-2)

86432 Reduction of intraocular pressure using timolol orally dissolving strips in the treatment of induced primary open-angle glaucoma in rabbits
Alolayan EM
Journal of Pharmacy and Pharmacology 2020; 72: 682-698 (IGR: 21-2)

86722 Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbits
Dosa PI
PLoS ONE 2020; 15: e0231841 (IGR: 21-2)

86651 Sustained subconjunctival delivery of cyclosporine A using thermogelling polymers for glaucoma filtration surgery
Yu L
Journal of materials chemistry. B 2017; 5: 6400-6411 (IGR: 21-2)

86844 Incorporation of ion exchange functionalized-montmorillonite into solid lipid nanoparticles with low irritation enhances drug bioavailability for glaucoma treatment
Yang F
Drug Delivery 2020; 27: 652-661 (IGR: 21-2)

86221 Tear Meniscus Imaging by Anterior Segment-Optical Coherence Tomography in Medically Controlled Glaucoma
Mastropasqua L
Journal of Glaucoma 2020; 29: 374-380 (IGR: 21-2)

86651 Sustained subconjunctival delivery of cyclosporine A using thermogelling polymers for glaucoma filtration surgery
Sun X
Journal of materials chemistry. B 2017; 5: 6400-6411 (IGR: 21-2)

86432 Reduction of intraocular pressure using timolol orally dissolving strips in the treatment of induced primary open-angle glaucoma in rabbits
El-Telbany DFA
Journal of Pharmacy and Pharmacology 2020; 72: 682-698 (IGR: 21-2)

86722 Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbits
Fautsch MP
PLoS ONE 2020; 15: e0231841 (IGR: 21-2)

86844 Incorporation of ion exchange functionalized-montmorillonite into solid lipid nanoparticles with low irritation enhances drug bioavailability for glaucoma treatment
Ping Q
Drug Delivery 2020; 27: 652-661 (IGR: 21-2)

86651 Sustained subconjunctival delivery of cyclosporine A using thermogelling polymers for glaucoma filtration surgery
Ding J
Journal of materials chemistry. B 2017; 5: 6400-6411 (IGR: 21-2)

86844 Incorporation of ion exchange functionalized-montmorillonite into solid lipid nanoparticles with low irritation enhances drug bioavailability for glaucoma treatment
Pan Y; Hou D
Drug Delivery 2020; 27: 652-661 (IGR: 21-2)

84508 Effects of topical autologous serum on the ocular surface in patients with toxic corneal epitheliopathy induced by anti-glaucoma drugs
Yoon CH
International Ophthalmology 2020; 40: 547-552 (IGR: 21-1)

84579 Brinzolamide loaded chitosan-pectin mucoadhesive nanocapsules for management of glaucoma: Formulation, characterization and pharmacodynamic study
Dubey V
International Journal of Biological Macromolecules 2020; 152: 1224-1232 (IGR: 21-1)

84829 24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients
Craven ER
Drugs 2020; 80: 167-179 (IGR: 21-1)

85089 Impact of Ocular Surface Disease Treatment in Patients with Glaucoma
Mylla Boso AL
Clinical Ophthalmology 2020; 14: 103-111 (IGR: 21-1)

85206 Promising therapeutic drug delivery systems for glaucoma: a comprehensive review
Singh RB
Therapeutic advances in ophthalmology 2020; 12: 2515841420905740 (IGR: 21-1)

84572 Dendritic Effects of Injectable Biodegradable Thermogels on Pharmacotherapy of Inflammatory Glaucoma-Associated Degradation of Extracellular Matrix
Nguyen DD
Advanced healthcare materials 2019; 8: e1900702 (IGR: 21-1)

84655 Benzoic acid derivative-modified chitosan-g-poly(N-isopropylacrylamide): Methoxylation effects and pharmacological treatments of Glaucoma-related neurodegeneration
Luo LJ
Journal of Controlled Release 2020; 317: 246-258 (IGR: 21-1)

85049 The Sustained Release of Tafluprost with a Drug Delivery System Prevents the Axonal Injury-induced Loss of Retinal Ganglion Cells in Rats
Sato K
Current Eye Research 2020; 0: 1-10 (IGR: 21-1)

85151 Mitochondrial Dysfunctions May Be One of the Major Causative Factors Underlying Detrimental Effects of Benzalkonium Chloride
Rogov AG
Oxidative medicine and cellular longevity 2020; 2020: 8956504 (IGR: 21-1)

84144 Proniosomal gel-derived niosomes: an approach to sustain and improve the ocular delivery of brimonidine tartrate; formulation, in-vitro characterization, and in-vivo pharmacodynamic study
Emad Eldeeb A
Drug Delivery 2019; 26: 509-521 (IGR: 21-1)

85206 Promising therapeutic drug delivery systems for glaucoma: a comprehensive review
Singh RB
Therapeutic advances in ophthalmology 2020; 12: 2515841420905740 (IGR: 21-1)

85091 Clinical Evaluation of a Novel Electromechanical Topical Ocular Drug Delivery System: Two Phase 1 Proof of Concept Studies
Quiroz-Mercado H
Clinical Ophthalmology 2020; 14: 139-147 (IGR: 21-1)

84873 The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 () Knockout Mice Treated with Antiglaucoma Eye Medications
Yagi-Yaguchi Y
Diagnostics (Basel, Switzerland) 2020; 10: (IGR: 21-1)

84927 Bimatoprost Imprinted Silicone Contact Lens to Treat Glaucoma
Yan F
AAPS PharmSciTech 2020; 21: 63 (IGR: 21-1)

85115 Albumin Levels in Tear Film Modulate the Bioavailability of Medically-Relevant Topical Drugs
Sebbag L
Frontiers in pharmacology 2019; 10: 1560 (IGR: 21-1)

84877 Ocular surface analysis and automatic non-invasive assessment of tear film breakup location, extension and progression in patients with glaucoma
Guarnieri A
BMC Ophthalmology 2020; 20: 12 (IGR: 21-1)

84241 Effects of rosiglitazone/PHBV drug delivery system on postoperative fibrosis in rabbit glaucoma filtration surgery model
Zhang F
Drug Delivery 2019; 26: 812-819 (IGR: 21-1)

84893 Sustained Nitric Oxide-Providing Small Molecule and Precise Release Behavior Study for Glaucoma Treatment
Jeong H
Molecular pharmaceutics 2020; 17: 656-665 (IGR: 21-1)

84963 Brinzolamide Dimethyl Sulfoxide In Situ Gelling Ophthalmic Solution: Formulation Optimisation and In Vitro and In Vivo Evaluation
Bhalerao H
AAPS PharmSciTech 2020; 21: 69 (IGR: 21-1)

84572 Dendritic Effects of Injectable Biodegradable Thermogels on Pharmacotherapy of Inflammatory Glaucoma-Associated Degradation of Extracellular Matrix
Nguyen DD
Advanced healthcare materials 2019; 8: e1900702 (IGR: 21-1)

84829 24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients
Walters T
Drugs 2020; 80: 167-179 (IGR: 21-1)

85115 Albumin Levels in Tear Film Modulate the Bioavailability of Medically-Relevant Topical Drugs
Moody LM
Frontiers in pharmacology 2019; 10: 1560 (IGR: 21-1)

85049 The Sustained Release of Tafluprost with a Drug Delivery System Prevents the Axonal Injury-induced Loss of Retinal Ganglion Cells in Rats
Nakagawa Y
Current Eye Research 2020; 0: 1-10 (IGR: 21-1)

85091 Clinical Evaluation of a Novel Electromechanical Topical Ocular Drug Delivery System: Two Phase 1 Proof of Concept Studies
Ivri E
Clinical Ophthalmology 2020; 14: 139-147 (IGR: 21-1)

84144 Proniosomal gel-derived niosomes: an approach to sustain and improve the ocular delivery of brimonidine tartrate; formulation, in-vitro characterization, and in-vivo pharmacodynamic study
Salah S
Drug Delivery 2019; 26: 509-521 (IGR: 21-1)

85206 Promising therapeutic drug delivery systems for glaucoma: a comprehensive review
Ichhpujani P
Therapeutic advances in ophthalmology 2020; 12: 2515841420905740 (IGR: 21-1)

84508 Effects of topical autologous serum on the ocular surface in patients with toxic corneal epitheliopathy induced by anti-glaucoma drugs
Lee HJ
International Ophthalmology 2020; 40: 547-552 (IGR: 21-1)

85089 Impact of Ocular Surface Disease Treatment in Patients with Glaucoma
Gasperi E
Clinical Ophthalmology 2020; 14: 103-111 (IGR: 21-1)

84873 The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 () Knockout Mice Treated with Antiglaucoma Eye Medications
Kojima T
Diagnostics (Basel, Switzerland) 2020; 10: (IGR: 21-1)

84927 Bimatoprost Imprinted Silicone Contact Lens to Treat Glaucoma
Liu Y
AAPS PharmSciTech 2020; 21: 63 (IGR: 21-1)

84572 Dendritic Effects of Injectable Biodegradable Thermogels on Pharmacotherapy of Inflammatory Glaucoma-Associated Degradation of Extracellular Matrix
Luo LJ
Advanced healthcare materials 2019; 8: e1900702 (IGR: 21-1)

84963 Brinzolamide Dimethyl Sulfoxide In Situ Gelling Ophthalmic Solution: Formulation Optimisation and In Vitro and In Vivo Evaluation
Koteshwara KB
AAPS PharmSciTech 2020; 21: 69 (IGR: 21-1)

84893 Sustained Nitric Oxide-Providing Small Molecule and Precise Release Behavior Study for Glaucoma Treatment
Park S
Molecular pharmaceutics 2020; 17: 656-665 (IGR: 21-1)

84877 Ocular surface analysis and automatic non-invasive assessment of tear film breakup location, extension and progression in patients with glaucoma
Carnero E
BMC Ophthalmology 2020; 20: 12 (IGR: 21-1)

84655 Benzoic acid derivative-modified chitosan-g-poly(N-isopropylacrylamide): Methoxylation effects and pharmacological treatments of Glaucoma-related neurodegeneration
Nguyen DD
Journal of Controlled Release 2020; 317: 246-258 (IGR: 21-1)

84579 Brinzolamide loaded chitosan-pectin mucoadhesive nanocapsules for management of glaucoma: Formulation, characterization and pharmacodynamic study
Mohan P
International Journal of Biological Macromolecules 2020; 152: 1224-1232 (IGR: 21-1)

84241 Effects of rosiglitazone/PHBV drug delivery system on postoperative fibrosis in rabbit glaucoma filtration surgery model
Liu K
Drug Delivery 2019; 26: 812-819 (IGR: 21-1)

85151 Mitochondrial Dysfunctions May Be One of the Major Causative Factors Underlying Detrimental Effects of Benzalkonium Chloride
Goleva TN
Oxidative medicine and cellular longevity 2020; 2020: 8956504 (IGR: 21-1)

84877 Ocular surface analysis and automatic non-invasive assessment of tear film breakup location, extension and progression in patients with glaucoma
Carnero E
BMC Ophthalmology 2020; 20: 12 (IGR: 21-1)

84655 Benzoic acid derivative-modified chitosan-g-poly(N-isopropylacrylamide): Methoxylation effects and pharmacological treatments of Glaucoma-related neurodegeneration
Nguyen DD
Journal of Controlled Release 2020; 317: 246-258 (IGR: 21-1)

84963 Brinzolamide Dimethyl Sulfoxide In Situ Gelling Ophthalmic Solution: Formulation Optimisation and In Vitro and In Vivo Evaluation
Chandran S
AAPS PharmSciTech 2020; 21: 69 (IGR: 21-1)

85151 Mitochondrial Dysfunctions May Be One of the Major Causative Factors Underlying Detrimental Effects of Benzalkonium Chloride
Sukhanova EI
Oxidative medicine and cellular longevity 2020; 2020: 8956504 (IGR: 21-1)

84877 Ocular surface analysis and automatic non-invasive assessment of tear film breakup location, extension and progression in patients with glaucoma
Bleau AM
BMC Ophthalmology 2020; 20: 12 (IGR: 21-1)

84927 Bimatoprost Imprinted Silicone Contact Lens to Treat Glaucoma
Han S
AAPS PharmSciTech 2020; 21: 63 (IGR: 21-1)

85115 Albumin Levels in Tear Film Modulate the Bioavailability of Medically-Relevant Topical Drugs
Mochel JP
Frontiers in pharmacology 2019; 10: 1560 (IGR: 21-1)

84579 Brinzolamide loaded chitosan-pectin mucoadhesive nanocapsules for management of glaucoma: Formulation, characterization and pharmacodynamic study
Dangi JS
International Journal of Biological Macromolecules 2020; 152: 1224-1232 (IGR: 21-1)

84508 Effects of topical autologous serum on the ocular surface in patients with toxic corneal epitheliopathy induced by anti-glaucoma drugs
Park HY
International Ophthalmology 2020; 40: 547-552 (IGR: 21-1)

84877 Ocular surface analysis and automatic non-invasive assessment of tear film breakup location, extension and progression in patients with glaucoma
Bleau AM
BMC Ophthalmology 2020; 20: 12 (IGR: 21-1)

84241 Effects of rosiglitazone/PHBV drug delivery system on postoperative fibrosis in rabbit glaucoma filtration surgery model
Pan Z
Drug Delivery 2019; 26: 812-819 (IGR: 21-1)

84655 Benzoic acid derivative-modified chitosan-g-poly(N-isopropylacrylamide): Methoxylation effects and pharmacological treatments of Glaucoma-related neurodegeneration
Lai JY
Journal of Controlled Release 2020; 317: 246-258 (IGR: 21-1)

85049 The Sustained Release of Tafluprost with a Drug Delivery System Prevents the Axonal Injury-induced Loss of Retinal Ganglion Cells in Rats
Omodaka K
Current Eye Research 2020; 0: 1-10 (IGR: 21-1)

85089 Impact of Ocular Surface Disease Treatment in Patients with Glaucoma
Fernandes L
Clinical Ophthalmology 2020; 14: 103-111 (IGR: 21-1)

85091 Clinical Evaluation of a Novel Electromechanical Topical Ocular Drug Delivery System: Two Phase 1 Proof of Concept Studies
Gonzalez-Salinas R
Clinical Ophthalmology 2020; 14: 139-147 (IGR: 21-1)

84144 Proniosomal gel-derived niosomes: an approach to sustain and improve the ocular delivery of brimonidine tartrate; formulation, in-vitro characterization, and in-vivo pharmacodynamic study
Ghorab M
Drug Delivery 2019; 26: 509-521 (IGR: 21-1)

85206 Promising therapeutic drug delivery systems for glaucoma: a comprehensive review
Thakur S
Therapeutic advances in ophthalmology 2020; 12: 2515841420905740 (IGR: 21-1)

84572 Dendritic Effects of Injectable Biodegradable Thermogels on Pharmacotherapy of Inflammatory Glaucoma-Associated Degradation of Extracellular Matrix
Lai JY
Advanced healthcare materials 2019; 8: e1900702 (IGR: 21-1)

84829 24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients
Christie WC
Drugs 2020; 80: 167-179 (IGR: 21-1)

84893 Sustained Nitric Oxide-Providing Small Molecule and Precise Release Behavior Study for Glaucoma Treatment
Park K
Molecular pharmaceutics 2020; 17: 656-665 (IGR: 21-1)

84873 The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 () Knockout Mice Treated with Antiglaucoma Eye Medications
Higa K
Diagnostics (Basel, Switzerland) 2020; 10: (IGR: 21-1)

85206 Promising therapeutic drug delivery systems for glaucoma: a comprehensive review
Jindal S
Therapeutic advances in ophthalmology 2020; 12: 2515841420905740 (IGR: 21-1)

85151 Mitochondrial Dysfunctions May Be One of the Major Causative Factors Underlying Detrimental Effects of Benzalkonium Chloride
Epremyan KK
Oxidative medicine and cellular longevity 2020; 2020: 8956504 (IGR: 21-1)

85089 Impact of Ocular Surface Disease Treatment in Patients with Glaucoma
Costa VP
Clinical Ophthalmology 2020; 14: 103-111 (IGR: 21-1)

84873 The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 () Knockout Mice Treated with Antiglaucoma Eye Medications
Dogru M
Diagnostics (Basel, Switzerland) 2020; 10: (IGR: 21-1)

84893 Sustained Nitric Oxide-Providing Small Molecule and Precise Release Behavior Study for Glaucoma Treatment
Kim M
Molecular pharmaceutics 2020; 17: 656-665 (IGR: 21-1)

84927 Bimatoprost Imprinted Silicone Contact Lens to Treat Glaucoma
Zhao Q
AAPS PharmSciTech 2020; 21: 63 (IGR: 21-1)

84829 24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients
Day DG
Drugs 2020; 80: 167-179 (IGR: 21-1)

84877 Ocular surface analysis and automatic non-invasive assessment of tear film breakup location, extension and progression in patients with glaucoma
López de Aguileta Castaño N
BMC Ophthalmology 2020; 20: 12 (IGR: 21-1)

84579 Brinzolamide loaded chitosan-pectin mucoadhesive nanocapsules for management of glaucoma: Formulation, characterization and pharmacodynamic study
Kesavan K
International Journal of Biological Macromolecules 2020; 152: 1224-1232 (IGR: 21-1)

84508 Effects of topical autologous serum on the ocular surface in patients with toxic corneal epitheliopathy induced by anti-glaucoma drugs
Kim H
International Ophthalmology 2020; 40: 547-552 (IGR: 21-1)

85091 Clinical Evaluation of a Novel Electromechanical Topical Ocular Drug Delivery System: Two Phase 1 Proof of Concept Studies
Kourtis IC
Clinical Ophthalmology 2020; 14: 139-147 (IGR: 21-1)

84241 Effects of rosiglitazone/PHBV drug delivery system on postoperative fibrosis in rabbit glaucoma filtration surgery model
Cao M
Drug Delivery 2019; 26: 812-819 (IGR: 21-1)

85049 The Sustained Release of Tafluprost with a Drug Delivery System Prevents the Axonal Injury-induced Loss of Retinal Ganglion Cells in Rats
Asada H
Current Eye Research 2020; 0: 1-10 (IGR: 21-1)

85089 Impact of Ocular Surface Disease Treatment in Patients with Glaucoma
Alves M
Clinical Ophthalmology 2020; 14: 103-111 (IGR: 21-1)

84893 Sustained Nitric Oxide-Providing Small Molecule and Precise Release Behavior Study for Glaucoma Treatment
Hong J
Molecular pharmaceutics 2020; 17: 656-665 (IGR: 21-1)

84877 Ocular surface analysis and automatic non-invasive assessment of tear film breakup location, extension and progression in patients with glaucoma
Llorente Ortega M
BMC Ophthalmology 2020; 20: 12 (IGR: 21-1)

84241 Effects of rosiglitazone/PHBV drug delivery system on postoperative fibrosis in rabbit glaucoma filtration surgery model
Zhou D
Drug Delivery 2019; 26: 812-819 (IGR: 21-1)

85091 Clinical Evaluation of a Novel Electromechanical Topical Ocular Drug Delivery System: Two Phase 1 Proof of Concept Studies
Gilbert J
Clinical Ophthalmology 2020; 14: 139-147 (IGR: 21-1)

84873 The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 () Knockout Mice Treated with Antiglaucoma Eye Medications
Ibrahim OM
Diagnostics (Basel, Switzerland) 2020; 10: (IGR: 21-1)

84508 Effects of topical autologous serum on the ocular surface in patients with toxic corneal epitheliopathy induced by anti-glaucoma drugs
Kim MK
International Ophthalmology 2020; 40: 547-552 (IGR: 21-1)

85049 The Sustained Release of Tafluprost with a Drug Delivery System Prevents the Axonal Injury-induced Loss of Retinal Ganglion Cells in Rats
Fujii S
Current Eye Research 2020; 0: 1-10 (IGR: 21-1)

84829 24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients
Lewis RA
Drugs 2020; 80: 167-179 (IGR: 21-1)

85151 Mitochondrial Dysfunctions May Be One of the Major Causative Factors Underlying Detrimental Effects of Benzalkonium Chloride
Trendeleva TA
Oxidative medicine and cellular longevity 2020; 2020: 8956504 (IGR: 21-1)

84927 Bimatoprost Imprinted Silicone Contact Lens to Treat Glaucoma
Liu N
AAPS PharmSciTech 2020; 21: 63 (IGR: 21-1)

84877 Ocular surface analysis and automatic non-invasive assessment of tear film breakup location, extension and progression in patients with glaucoma
Moreno-Montañés J
BMC Ophthalmology 2020; 20: 12 (IGR: 21-1)

84241 Effects of rosiglitazone/PHBV drug delivery system on postoperative fibrosis in rabbit glaucoma filtration surgery model
Liu H
Drug Delivery 2019; 26: 812-819 (IGR: 21-1)

84873 The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 () Knockout Mice Treated with Antiglaucoma Eye Medications
Shimizu T
Diagnostics (Basel, Switzerland) 2020; 10: (IGR: 21-1)

85049 The Sustained Release of Tafluprost with a Drug Delivery System Prevents the Axonal Injury-induced Loss of Retinal Ganglion Cells in Rats
Masaki K
Current Eye Research 2020; 0: 1-10 (IGR: 21-1)

85091 Clinical Evaluation of a Novel Electromechanical Topical Ocular Drug Delivery System: Two Phase 1 Proof of Concept Studies
Pérez-Vázquez JF
Clinical Ophthalmology 2020; 14: 139-147 (IGR: 21-1)

85151 Mitochondrial Dysfunctions May Be One of the Major Causative Factors Underlying Detrimental Effects of Benzalkonium Chloride
Ovchenkova AP
Oxidative medicine and cellular longevity 2020; 2020: 8956504 (IGR: 21-1)

84508 Effects of topical autologous serum on the ocular surface in patients with toxic corneal epitheliopathy induced by anti-glaucoma drugs
Jeoung JW
International Ophthalmology 2020; 40: 547-552 (IGR: 21-1)

84829 24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients
Goodkin ML
Drugs 2020; 80: 167-179 (IGR: 21-1)

84873 The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 () Knockout Mice Treated with Antiglaucoma Eye Medications
Tsubota K
Diagnostics (Basel, Switzerland) 2020; 10: (IGR: 21-1)

84508 Effects of topical autologous serum on the ocular surface in patients with toxic corneal epitheliopathy induced by anti-glaucoma drugs
Oh JY
International Ophthalmology 2020; 40: 547-552 (IGR: 21-1)

85049 The Sustained Release of Tafluprost with a Drug Delivery System Prevents the Axonal Injury-induced Loss of Retinal Ganglion Cells in Rats
Nakazawa T
Current Eye Research 2020; 0: 1-10 (IGR: 21-1)

84829 24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients
Chen M
Drugs 2020; 80: 167-179 (IGR: 21-1)

84241 Effects of rosiglitazone/PHBV drug delivery system on postoperative fibrosis in rabbit glaucoma filtration surgery model
Huang Y
Drug Delivery 2019; 26: 812-819 (IGR: 21-1)

85091 Clinical Evaluation of a Novel Electromechanical Topical Ocular Drug Delivery System: Two Phase 1 Proof of Concept Studies
Blumenkranz M
Clinical Ophthalmology 2020; 14: 139-147 (IGR: 21-1)

85151 Mitochondrial Dysfunctions May Be One of the Major Causative Factors Underlying Detrimental Effects of Benzalkonium Chloride
Aliverdieva DA
Oxidative medicine and cellular longevity 2020; 2020: 8956504 (IGR: 21-1)

85091 Clinical Evaluation of a Novel Electromechanical Topical Ocular Drug Delivery System: Two Phase 1 Proof of Concept Studies
Jiménez-Román J
Clinical Ophthalmology 2020; 14: 139-147 (IGR: 21-1)

84829 24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients
Wangsadipura V
Drugs 2020; 80: 167-179 (IGR: 21-1)

84241 Effects of rosiglitazone/PHBV drug delivery system on postoperative fibrosis in rabbit glaucoma filtration surgery model
Duan X
Drug Delivery 2019; 26: 812-819 (IGR: 21-1)

85151 Mitochondrial Dysfunctions May Be One of the Major Causative Factors Underlying Detrimental Effects of Benzalkonium Chloride
Zvyagilskaya RA
Oxidative medicine and cellular longevity 2020; 2020: 8956504 (IGR: 21-1)

84873 The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 () Knockout Mice Treated with Antiglaucoma Eye Medications
Shimazaki J
Diagnostics (Basel, Switzerland) 2020; 10: (IGR: 21-1)

84829 24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients
Robinson MR
Drugs 2020; 80: 167-179 (IGR: 21-1)

85091 Clinical Evaluation of a Novel Electromechanical Topical Ocular Drug Delivery System: Two Phase 1 Proof of Concept Studies
Marcellino G
Clinical Ophthalmology 2020; 14: 139-147 (IGR: 21-1)

84829 24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients
Bejanian M;
Drugs 2020; 80: 167-179 (IGR: 21-1)

82430 Latanoprost uptake and release from commercial contact lenses
Horne RR
Journal of Biomaterials Science, Polymer Edition 2020; 31: 1-19 (IGR: 20-4)

82587 Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019
Supuran CT
Expert Opinion on Therapeutic Patents 2019; 29: 781-792 (IGR: 20-4)

82052 Effect of topical glaucoma medication on tear lipid layer thickness in patients with unilateral glaucoma
Lee SM
Indian Journal of Ophthalmology 2019; 67: 1297-1302 (IGR: 20-4)

82159 Tear neuromediators in eyes on chronic topical antiglaucoma therapy with and without BAK preservatives
Murugesan V
British Journal of Ophthalmology 2019; 0: (IGR: 20-4)

82708 Promising Approach in the Treatment of Glaucoma Using Nanotechnology and Nanomedicine-Based Systems
Juliana FR
Molecules 2019; 24: (IGR: 20-4)

82710 Targeted Drug Delivery Systems for the Treatment of Glaucoma: Most Advanced Systems Review
Cegielska O
Polymers 2019; 11: (IGR: 20-4)

82367 Chitosan/hydroxyethyl cellulose inserts for sustained-release of dorzolamide for glaucoma treatment: In vitro and in vivo evaluation
Franca JR
International Journal of Pharmaceutics 2019; 570: 118662 (IGR: 20-4)

82571 Δ-Tetrahydrocannabinol Derivative-Loaded Nanoformulation Lowers Intraocular Pressure in Normotensive Rabbits
Taskar PS
Translational vision science & technology 2019; 8: 15 (IGR: 20-4)

82599 Applications of microneedles in delivering drugs for various ocular diseases
Gupta P
Life Sciences 2019; 237: 116907 (IGR: 20-4)

82613 Preservative-free preserved brimonidine %0.15 preparations in the treatment of glaucoma and ocular hypertension: short term evaluation of efficacy, safety, and potential advantages
Duru Z
Cutaneous and Ocular Toxicology 2020; 39: 21-24 (IGR: 20-4)

82174 The Impact of R-801 Nanoparticles as a Long Acting Topical Glaucoma Therapy
Ibrahim MM
Journal of biomedical nanotechnology 2019; 15: 1968-1981 (IGR: 20-4)

82350 Safety data on in situ gelling bimatoprost loaded nanovesicular formulations
Yadav M
Data in brief 2019; 25: 104361 (IGR: 20-4)

82590 Effects of Preservative on the Meibomian Gland in Glaucoma Patients Treated with Prostaglandin Analogues
Ha JY
Chonnam medical journal 2019; 55: 156-162 (IGR: 20-4)

82239 Leucaena leucocephala (Lam.) galactomannan nanoparticles: Optimization and characterization for ocular delivery in glaucoma treatment
Mittal N
International Journal of Biological Macromolecules 2019; 139: 1252-1262 (IGR: 20-4)

82758 Ocular Surface Disease with BAK preserved Travoprost and Polyquaternium 1(Polyquad) preserved Travoprost
Kumar S
Romanian journal of ophthalmology 2019; 63: 249-256 (IGR: 20-4)

82708 Promising Approach in the Treatment of Glaucoma Using Nanotechnology and Nanomedicine-Based Systems
Kesse S
Molecules 2019; 24: (IGR: 20-4)

82590 Effects of Preservative on the Meibomian Gland in Glaucoma Patients Treated with Prostaglandin Analogues
Sung MS
Chonnam medical journal 2019; 55: 156-162 (IGR: 20-4)

82239 Leucaena leucocephala (Lam.) galactomannan nanoparticles: Optimization and characterization for ocular delivery in glaucoma treatment
Kaur G
International Journal of Biological Macromolecules 2019; 139: 1252-1262 (IGR: 20-4)

82710 Targeted Drug Delivery Systems for the Treatment of Glaucoma: Most Advanced Systems Review
Sajkiewicz P
Polymers 2019; 11: (IGR: 20-4)

82599 Applications of microneedles in delivering drugs for various ocular diseases
Yadav KS
Life Sciences 2019; 237: 116907 (IGR: 20-4)

82758 Ocular Surface Disease with BAK preserved Travoprost and Polyquaternium 1(Polyquad) preserved Travoprost
Singh T
Romanian journal of ophthalmology 2019; 63: 249-256 (IGR: 20-4)

82613 Preservative-free preserved brimonidine %0.15 preparations in the treatment of glaucoma and ocular hypertension: short term evaluation of efficacy, safety, and potential advantages
Ozsaygili C
Cutaneous and Ocular Toxicology 2020; 39: 21-24 (IGR: 20-4)

82174 The Impact of R-801 Nanoparticles as a Long Acting Topical Glaucoma Therapy
Jablonski MM
Journal of biomedical nanotechnology 2019; 15: 1968-1981 (IGR: 20-4)

82350 Safety data on in situ gelling bimatoprost loaded nanovesicular formulations
Guzman-Aranguez A
Data in brief 2019; 25: 104361 (IGR: 20-4)

82052 Effect of topical glaucoma medication on tear lipid layer thickness in patients with unilateral glaucoma
Lee JE
Indian Journal of Ophthalmology 2019; 67: 1297-1302 (IGR: 20-4)

82571 Δ-Tetrahydrocannabinol Derivative-Loaded Nanoformulation Lowers Intraocular Pressure in Normotensive Rabbits
Patil A
Translational vision science & technology 2019; 8: 15 (IGR: 20-4)

82430 Latanoprost uptake and release from commercial contact lenses
Rich JT
Journal of Biomaterials Science, Polymer Edition 2020; 31: 1-19 (IGR: 20-4)

82587 Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019
Altamimi ASA
Expert Opinion on Therapeutic Patents 2019; 29: 781-792 (IGR: 20-4)

82367 Chitosan/hydroxyethyl cellulose inserts for sustained-release of dorzolamide for glaucoma treatment: In vitro and in vivo evaluation
Foureaux G
International Journal of Pharmaceutics 2019; 570: 118662 (IGR: 20-4)

82159 Tear neuromediators in eyes on chronic topical antiglaucoma therapy with and without BAK preservatives
Dwivedi R
British Journal of Ophthalmology 2019; 0: (IGR: 20-4)

82599 Applications of microneedles in delivering drugs for various ocular diseases
Yadav KS
Life Sciences 2019; 237: 116907 (IGR: 20-4)

82571 Δ-Tetrahydrocannabinol Derivative-Loaded Nanoformulation Lowers Intraocular Pressure in Normotensive Rabbits
Lakhani P
Translational vision science & technology 2019; 8: 15 (IGR: 20-4)

82350 Safety data on in situ gelling bimatoprost loaded nanovesicular formulations
Perez De Lara MJ
Data in brief 2019; 25: 104361 (IGR: 20-4)

82590 Effects of Preservative on the Meibomian Gland in Glaucoma Patients Treated with Prostaglandin Analogues
Park SW
Chonnam medical journal 2019; 55: 156-162 (IGR: 20-4)

82430 Latanoprost uptake and release from commercial contact lenses
Bradley MW
Journal of Biomaterials Science, Polymer Edition 2020; 31: 1-19 (IGR: 20-4)

82159 Tear neuromediators in eyes on chronic topical antiglaucoma therapy with and without BAK preservatives
Saini M
British Journal of Ophthalmology 2019; 0: (IGR: 20-4)

82708 Promising Approach in the Treatment of Glaucoma Using Nanotechnology and Nanomedicine-Based Systems
Boakye-Yiadom KO
Molecules 2019; 24: (IGR: 20-4)

82758 Ocular Surface Disease with BAK preserved Travoprost and Polyquaternium 1(Polyquad) preserved Travoprost
Ichhpujani P
Romanian journal of ophthalmology 2019; 63: 249-256 (IGR: 20-4)

82367 Chitosan/hydroxyethyl cellulose inserts for sustained-release of dorzolamide for glaucoma treatment: In vitro and in vivo evaluation
Fuscaldi LL
International Journal of Pharmaceutics 2019; 570: 118662 (IGR: 20-4)

82052 Effect of topical glaucoma medication on tear lipid layer thickness in patients with unilateral glaucoma
Kim SI
Indian Journal of Ophthalmology 2019; 67: 1297-1302 (IGR: 20-4)

82587 Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019
Carta F
Expert Opinion on Therapeutic Patents 2019; 29: 781-792 (IGR: 20-4)

82350 Safety data on in situ gelling bimatoprost loaded nanovesicular formulations
Singh M
Data in brief 2019; 25: 104361 (IGR: 20-4)

82758 Ocular Surface Disease with BAK preserved Travoprost and Polyquaternium 1(Polyquad) preserved Travoprost
Vohra S
Romanian journal of ophthalmology 2019; 63: 249-256 (IGR: 20-4)

82367 Chitosan/hydroxyethyl cellulose inserts for sustained-release of dorzolamide for glaucoma treatment: In vitro and in vivo evaluation
Ribeiro TG
International Journal of Pharmaceutics 2019; 570: 118662 (IGR: 20-4)

82571 Δ-Tetrahydrocannabinol Derivative-Loaded Nanoformulation Lowers Intraocular Pressure in Normotensive Rabbits
Ashour E
Translational vision science & technology 2019; 8: 15 (IGR: 20-4)

82159 Tear neuromediators in eyes on chronic topical antiglaucoma therapy with and without BAK preservatives
Gupta V
British Journal of Ophthalmology 2019; 0: (IGR: 20-4)

82708 Promising Approach in the Treatment of Glaucoma Using Nanotechnology and Nanomedicine-Based Systems
Veroniaina H
Molecules 2019; 24: (IGR: 20-4)

82052 Effect of topical glaucoma medication on tear lipid layer thickness in patients with unilateral glaucoma
Jung JH
Indian Journal of Ophthalmology 2019; 67: 1297-1302 (IGR: 20-4)

82430 Latanoprost uptake and release from commercial contact lenses
Pitt WG
Journal of Biomaterials Science, Polymer Edition 2020; 31: 1-19 (IGR: 20-4)

82159 Tear neuromediators in eyes on chronic topical antiglaucoma therapy with and without BAK preservatives
Dada T
British Journal of Ophthalmology 2019; 0: (IGR: 20-4)

82708 Promising Approach in the Treatment of Glaucoma Using Nanotechnology and Nanomedicine-Based Systems
Wang H
Molecules 2019; 24: (IGR: 20-4)

82571 Δ-Tetrahydrocannabinol Derivative-Loaded Nanoformulation Lowers Intraocular Pressure in Normotensive Rabbits
Gul W
Translational vision science & technology 2019; 8: 15 (IGR: 20-4)

82350 Safety data on in situ gelling bimatoprost loaded nanovesicular formulations
Singh J
Data in brief 2019; 25: 104361 (IGR: 20-4)

82367 Chitosan/hydroxyethyl cellulose inserts for sustained-release of dorzolamide for glaucoma treatment: In vitro and in vivo evaluation
Castilho RO
International Journal of Pharmaceutics 2019; 570: 118662 (IGR: 20-4)

82052 Effect of topical glaucoma medication on tear lipid layer thickness in patients with unilateral glaucoma
Shin J
Indian Journal of Ophthalmology 2019; 67: 1297-1302 (IGR: 20-4)

82571 Δ-Tetrahydrocannabinol Derivative-Loaded Nanoformulation Lowers Intraocular Pressure in Normotensive Rabbits
Elsohly MA
Translational vision science & technology 2019; 8: 15 (IGR: 20-4)

82350 Safety data on in situ gelling bimatoprost loaded nanovesicular formulations
Kaur IP
Data in brief 2019; 25: 104361 (IGR: 20-4)

82367 Chitosan/hydroxyethyl cellulose inserts for sustained-release of dorzolamide for glaucoma treatment: In vitro and in vivo evaluation
Yoshida MI
International Journal of Pharmaceutics 2019; 570: 118662 (IGR: 20-4)

82708 Promising Approach in the Treatment of Glaucoma Using Nanotechnology and Nanomedicine-Based Systems
Sun M
Molecules 2019; 24: (IGR: 20-4)

82159 Tear neuromediators in eyes on chronic topical antiglaucoma therapy with and without BAK preservatives
Vivekanandhan S
British Journal of Ophthalmology 2019; 0: (IGR: 20-4)

82367 Chitosan/hydroxyethyl cellulose inserts for sustained-release of dorzolamide for glaucoma treatment: In vitro and in vivo evaluation
Cardoso VN
International Journal of Pharmaceutics 2019; 570: 118662 (IGR: 20-4)

82571 Δ-Tetrahydrocannabinol Derivative-Loaded Nanoformulation Lowers Intraocular Pressure in Normotensive Rabbits
Murphy B
Translational vision science & technology 2019; 8: 15 (IGR: 20-4)

82367 Chitosan/hydroxyethyl cellulose inserts for sustained-release of dorzolamide for glaucoma treatment: In vitro and in vivo evaluation
Fernandes SOA
International Journal of Pharmaceutics 2019; 570: 118662 (IGR: 20-4)

82571 Δ-Tetrahydrocannabinol Derivative-Loaded Nanoformulation Lowers Intraocular Pressure in Normotensive Rabbits
Majumdar S
Translational vision science & technology 2019; 8: 15 (IGR: 20-4)

82367 Chitosan/hydroxyethyl cellulose inserts for sustained-release of dorzolamide for glaucoma treatment: In vitro and in vivo evaluation
Cronemberger S; Nogueira JC; Ferreira AJ; Faraco AAG
International Journal of Pharmaceutics 2019; 570: 118662 (IGR: 20-4)

81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
Aptel F
Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)

80622 An in vivo confocal, prospective, masked, 36 months study on glaucoma patients medically treated with preservative-free or preserved monotherapy
Rossi GCM
Scientific reports 2019; 9: 4282 (IGR: 20-3)

80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension
Aptel F
Journal of Glaucoma 2019; 0: (IGR: 20-3)

80528 Effect of 2 Novel Sustained-release Drug Release Systems on Bleb Fibrosis: An In Vivo Trabeculectomy Study in a Rabbit Model
Swann FB
Journal of Glaucoma 2019; 28: 512-518 (IGR: 20-3)

80678 Topical application of polymeric nanomicelles in ophthalmology: a review on research efforts for the noninvasive delivery of ocular therapeutics
Grimaudo MA
Expert Opinion on Drug Delivery 2019; 16: 397-413 (IGR: 20-3)

81199 Designing of a pH-Triggered Carbopol®/HPMC In Situ Gel for Ocular Delivery of Dorzolamide HCl: In Vitro, In Vivo, and Ex Vivo Evaluation
Kouchak M
AAPS PharmSciTech 2019; 20: 210 (IGR: 20-3)

80517 Glaucoma: Current treatment and impact of advanced drug delivery systems
Yadav KS
Life Sciences 2019; 221: 362-376 (IGR: 20-3)

81017 Extracellular MMP-9-Based Assessment of Ocular Surface Inflammation in Patients with Primary Open-Angle Glaucoma
Zaleska-Żmijewska A
Journal of Ophthalmology 2019; 2019: 1240537 (IGR: 20-3)

81447 Bimatoprost loaded nanovesicular long-acting sub-conjunctival in-situ gelling implant: In vitro and in vivo evaluation
Yadav M
Materials science & engineering. C, Materials for biological applications 2019; 103: 109730 (IGR: 20-3)

81070 Co-delivery of latanoprost and timolol from micelles-laden contact lenses for the treatment of glaucoma
Xu J
Journal of Controlled Release 2019; 305: 18-28 (IGR: 20-3)

80694 Patient-Reported Nonadherence with Glaucoma Therapy
Wolfram C
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 223-228 (IGR: 20-3)

80907 Effect of Ultra-Small Chitosan Nanoparticles Doped with Brimonidine on the Ultra-Structure of the Trabecular Meshwork of Glaucoma Patients
Barwal I
Microscopy and microanalysis : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada 2019; 0: 1-15 (IGR: 20-3)

80720 Causative glaucoma treatment: promising targets and delivery systems
Mietzner R
Drug Discovery Today 2019; 24: 1606-1613 (IGR: 20-3)

80517 Glaucoma: Current treatment and impact of advanced drug delivery systems
Yadav KS
Life Sciences 2019; 221: 362-376 (IGR: 20-3)

81169 Osmoprotectants in Hybrid Liposome/HPMC Systems as Potential Glaucoma Treatment
Gómez-Ballesteros M
Polymers 2019; 11: (IGR: 20-3)

80765 Ocular Surface Evaluation After the Substitution of Benzalkonium Chloride Preserved Prostaglandin Eye Drops by a Preservative-free Prostaglandin Analogue
Lopes NLV
Medical hypothesis, discovery and innovation in ophthalmology 2019; 8: 52-56 (IGR: 20-3)

81061 Tear Film, Conjunctival and Corneal Modifications Induced by Glaucoma Treatment
Roberti G
Current Medicinal Chemistry 2019; 0: (IGR: 20-3)

81134 Development and evaluation of performance characteristics of timolol-loaded composite ocular films as potential delivery platforms for treatment of glaucoma
Tighsazzadeh M
International Journal of Pharmaceutics 2019; 566: 111-125 (IGR: 20-3)

80907 Effect of Ultra-Small Chitosan Nanoparticles Doped with Brimonidine on the Ultra-Structure of the Trabecular Meshwork of Glaucoma Patients
Kumar R
Microscopy and microanalysis : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada 2019; 0: 1-15 (IGR: 20-3)

80720 Causative glaucoma treatment: promising targets and delivery systems
Breunig M
Drug Discovery Today 2019; 24: 1606-1613 (IGR: 20-3)

80517 Glaucoma: Current treatment and impact of advanced drug delivery systems
Rajpurohit R
Life Sciences 2019; 221: 362-376 (IGR: 20-3)

80765 Ocular Surface Evaluation After the Substitution of Benzalkonium Chloride Preserved Prostaglandin Eye Drops by a Preservative-free Prostaglandin Analogue
Gracitelli CPB
Medical hypothesis, discovery and innovation in ophthalmology 2019; 8: 52-56 (IGR: 20-3)

80622 An in vivo confocal, prospective, masked, 36 months study on glaucoma patients medically treated with preservative-free or preserved monotherapy
Scudeller L
Scientific reports 2019; 9: 4282 (IGR: 20-3)

81070 Co-delivery of latanoprost and timolol from micelles-laden contact lenses for the treatment of glaucoma
Ge Y
Journal of Controlled Release 2019; 305: 18-28 (IGR: 20-3)

81134 Development and evaluation of performance characteristics of timolol-loaded composite ocular films as potential delivery platforms for treatment of glaucoma
Mitchell JC
International Journal of Pharmaceutics 2019; 566: 111-125 (IGR: 20-3)

81017 Extracellular MMP-9-Based Assessment of Ocular Surface Inflammation in Patients with Primary Open-Angle Glaucoma
Strzemecka E
Journal of Ophthalmology 2019; 2019: 1240537 (IGR: 20-3)

81447 Bimatoprost loaded nanovesicular long-acting sub-conjunctival in-situ gelling implant: In vitro and in vivo evaluation
Guzman-Aranguez A
Materials science & engineering. C, Materials for biological applications 2019; 103: 109730 (IGR: 20-3)

80694 Patient-Reported Nonadherence with Glaucoma Therapy
Stahlberg E
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 223-228 (IGR: 20-3)

80528 Effect of 2 Novel Sustained-release Drug Release Systems on Bleb Fibrosis: An In Vivo Trabeculectomy Study in a Rabbit Model
Singh S
Journal of Glaucoma 2019; 28: 512-518 (IGR: 20-3)

80678 Topical application of polymeric nanomicelles in ophthalmology: a review on research efforts for the noninvasive delivery of ocular therapeutics
Pescina S
Expert Opinion on Drug Delivery 2019; 16: 397-413 (IGR: 20-3)

81061 Tear Film, Conjunctival and Corneal Modifications Induced by Glaucoma Treatment
Tanga L
Current Medicinal Chemistry 2019; 0: (IGR: 20-3)

81169 Osmoprotectants in Hybrid Liposome/HPMC Systems as Potential Glaucoma Treatment
López-Cano JJ
Polymers 2019; 11: (IGR: 20-3)

81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
Pfeiffer N
Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)

80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension
Pfeiffer N
Journal of Glaucoma 2019; 0: (IGR: 20-3)

81199 Designing of a pH-Triggered Carbopol®/HPMC In Situ Gel for Ocular Delivery of Dorzolamide HCl: In Vitro, In Vivo, and Ex Vivo Evaluation
Mahmoodzadeh M; Farrahi F
AAPS PharmSciTech 2019; 20: 210 (IGR: 20-3)

81447 Bimatoprost loaded nanovesicular long-acting sub-conjunctival in-situ gelling implant: In vitro and in vivo evaluation
Perez De Lara MJ
Materials science & engineering. C, Materials for biological applications 2019; 103: 109730 (IGR: 20-3)

80907 Effect of Ultra-Small Chitosan Nanoparticles Doped with Brimonidine on the Ultra-Structure of the Trabecular Meshwork of Glaucoma Patients
Dada T
Microscopy and microanalysis : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada 2019; 0: 1-15 (IGR: 20-3)

80517 Glaucoma: Current treatment and impact of advanced drug delivery systems
Sharma S
Life Sciences 2019; 221: 362-376 (IGR: 20-3)

81169 Osmoprotectants in Hybrid Liposome/HPMC Systems as Potential Glaucoma Treatment
Bravo-Osuna I
Polymers 2019; 11: (IGR: 20-3)

80765 Ocular Surface Evaluation After the Substitution of Benzalkonium Chloride Preserved Prostaglandin Eye Drops by a Preservative-free Prostaglandin Analogue
Chalita MR
Medical hypothesis, discovery and innovation in ophthalmology 2019; 8: 52-56 (IGR: 20-3)

81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
Schmickler S
Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)

81134 Development and evaluation of performance characteristics of timolol-loaded composite ocular films as potential delivery platforms for treatment of glaucoma
Boateng JS
International Journal of Pharmaceutics 2019; 566: 111-125 (IGR: 20-3)

80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension
Schmickler S
Journal of Glaucoma 2019; 0: (IGR: 20-3)

80528 Effect of 2 Novel Sustained-release Drug Release Systems on Bleb Fibrosis: An In Vivo Trabeculectomy Study in a Rabbit Model
Blake D
Journal of Glaucoma 2019; 28: 512-518 (IGR: 20-3)

80622 An in vivo confocal, prospective, masked, 36 months study on glaucoma patients medically treated with preservative-free or preserved monotherapy
Lumini C
Scientific reports 2019; 9: 4282 (IGR: 20-3)

80678 Topical application of polymeric nanomicelles in ophthalmology: a review on research efforts for the noninvasive delivery of ocular therapeutics
Padula C
Expert Opinion on Drug Delivery 2019; 16: 397-413 (IGR: 20-3)

81070 Co-delivery of latanoprost and timolol from micelles-laden contact lenses for the treatment of glaucoma
Bu R
Journal of Controlled Release 2019; 305: 18-28 (IGR: 20-3)

81061 Tear Film, Conjunctival and Corneal Modifications Induced by Glaucoma Treatment
Manni G
Current Medicinal Chemistry 2019; 0: (IGR: 20-3)

81017 Extracellular MMP-9-Based Assessment of Ocular Surface Inflammation in Patients with Primary Open-Angle Glaucoma
Wawrzyniak ZM
Journal of Ophthalmology 2019; 2019: 1240537 (IGR: 20-3)

80694 Patient-Reported Nonadherence with Glaucoma Therapy
Pfeiffer N
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 223-228 (IGR: 20-3)

81017 Extracellular MMP-9-Based Assessment of Ocular Surface Inflammation in Patients with Primary Open-Angle Glaucoma
Szaflik JP
Journal of Ophthalmology 2019; 2019: 1240537 (IGR: 20-3)

80678 Topical application of polymeric nanomicelles in ophthalmology: a review on research efforts for the noninvasive delivery of ocular therapeutics
Santi P
Expert Opinion on Drug Delivery 2019; 16: 397-413 (IGR: 20-3)

81061 Tear Film, Conjunctival and Corneal Modifications Induced by Glaucoma Treatment
Riva I
Current Medicinal Chemistry 2019; 0: (IGR: 20-3)

80622 An in vivo confocal, prospective, masked, 36 months study on glaucoma patients medically treated with preservative-free or preserved monotherapy
Mirabile AV
Scientific reports 2019; 9: 4282 (IGR: 20-3)

80907 Effect of Ultra-Small Chitosan Nanoparticles Doped with Brimonidine on the Ultra-Structure of the Trabecular Meshwork of Glaucoma Patients
Yadav SC
Microscopy and microanalysis : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada 2019; 0: 1-15 (IGR: 20-3)

80765 Ocular Surface Evaluation After the Substitution of Benzalkonium Chloride Preserved Prostaglandin Eye Drops by a Preservative-free Prostaglandin Analogue
de Faria NVL
Medical hypothesis, discovery and innovation in ophthalmology 2019; 8: 52-56 (IGR: 20-3)

81169 Osmoprotectants in Hybrid Liposome/HPMC Systems as Potential Glaucoma Treatment
Herrero-Vanrell R
Polymers 2019; 11: (IGR: 20-3)

80528 Effect of 2 Novel Sustained-release Drug Release Systems on Bleb Fibrosis: An In Vivo Trabeculectomy Study in a Rabbit Model
John V
Journal of Glaucoma 2019; 28: 512-518 (IGR: 20-3)

81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
Clarke J
Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)

81447 Bimatoprost loaded nanovesicular long-acting sub-conjunctival in-situ gelling implant: In vitro and in vivo evaluation
Singh M
Materials science & engineering. C, Materials for biological applications 2019; 103: 109730 (IGR: 20-3)

81070 Co-delivery of latanoprost and timolol from micelles-laden contact lenses for the treatment of glaucoma
Zhang A
Journal of Controlled Release 2019; 305: 18-28 (IGR: 20-3)

80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension
Clarke J; Lavín-Dapena C
Journal of Glaucoma 2019; 0: (IGR: 20-3)

80622 An in vivo confocal, prospective, masked, 36 months study on glaucoma patients medically treated with preservative-free or preserved monotherapy
Picasso E
Scientific reports 2019; 9: 4282 (IGR: 20-3)

81169 Osmoprotectants in Hybrid Liposome/HPMC Systems as Potential Glaucoma Treatment
Molina-Martínez IT
Polymers 2019; 11: (IGR: 20-3)

81447 Bimatoprost loaded nanovesicular long-acting sub-conjunctival in-situ gelling implant: In vitro and in vivo evaluation
Singh J
Materials science & engineering. C, Materials for biological applications 2019; 103: 109730 (IGR: 20-3)

81070 Co-delivery of latanoprost and timolol from micelles-laden contact lenses for the treatment of glaucoma
Feng S
Journal of Controlled Release 2019; 305: 18-28 (IGR: 20-3)

80678 Topical application of polymeric nanomicelles in ophthalmology: a review on research efforts for the noninvasive delivery of ocular therapeutics
Concheiro A
Expert Opinion on Drug Delivery 2019; 16: 397-413 (IGR: 20-3)

81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
Lavín-Dapena C
Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)

80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension
Lavín-Dapena C
Journal of Glaucoma 2019; 0: (IGR: 20-3)

80528 Effect of 2 Novel Sustained-release Drug Release Systems on Bleb Fibrosis: An In Vivo Trabeculectomy Study in a Rabbit Model
Le C
Journal of Glaucoma 2019; 28: 512-518 (IGR: 20-3)

81061 Tear Film, Conjunctival and Corneal Modifications Induced by Glaucoma Treatment
Verticchio AC
Current Medicinal Chemistry 2019; 0: (IGR: 20-3)

81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
Lavín-Dapena C
Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)

80528 Effect of 2 Novel Sustained-release Drug Release Systems on Bleb Fibrosis: An In Vivo Trabeculectomy Study in a Rabbit Model
Fullerton M
Journal of Glaucoma 2019; 28: 512-518 (IGR: 20-3)

81070 Co-delivery of latanoprost and timolol from micelles-laden contact lenses for the treatment of glaucoma
Wang J
Journal of Controlled Release 2019; 305: 18-28 (IGR: 20-3)

81447 Bimatoprost loaded nanovesicular long-acting sub-conjunctival in-situ gelling implant: In vitro and in vivo evaluation
Kaur IP
Materials science & engineering. C, Materials for biological applications 2019; 103: 109730 (IGR: 20-3)

81061 Tear Film, Conjunctival and Corneal Modifications Induced by Glaucoma Treatment
Berardo F
Current Medicinal Chemistry 2019; 0: (IGR: 20-3)

80678 Topical application of polymeric nanomicelles in ophthalmology: a review on research efforts for the noninvasive delivery of ocular therapeutics
Alvarez-Lorenzo C
Expert Opinion on Drug Delivery 2019; 16: 397-413 (IGR: 20-3)

81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
Moreno-Montañés J
Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)

80622 An in vivo confocal, prospective, masked, 36 months study on glaucoma patients medically treated with preservative-free or preserved monotherapy
Bettio F
Scientific reports 2019; 9: 4282 (IGR: 20-3)

80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension
Moreno-Montañés J
Journal of Glaucoma 2019; 0: (IGR: 20-3)

81070 Co-delivery of latanoprost and timolol from micelles-laden contact lenses for the treatment of glaucoma
Gou J
Journal of Controlled Release 2019; 305: 18-28 (IGR: 20-3)

80528 Effect of 2 Novel Sustained-release Drug Release Systems on Bleb Fibrosis: An In Vivo Trabeculectomy Study in a Rabbit Model
Margo C
Journal of Glaucoma 2019; 28: 512-518 (IGR: 20-3)

81061 Tear Film, Conjunctival and Corneal Modifications Induced by Glaucoma Treatment
Carnevale C
Current Medicinal Chemistry 2019; 0: (IGR: 20-3)

80622 An in vivo confocal, prospective, masked, 36 months study on glaucoma patients medically treated with preservative-free or preserved monotherapy
Pasinetti GM
Scientific reports 2019; 9: 4282 (IGR: 20-3)

81061 Tear Film, Conjunctival and Corneal Modifications Induced by Glaucoma Treatment
Carnevale C
Current Medicinal Chemistry 2019; 0: (IGR: 20-3)

81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
Żarnowski T
Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)

80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension
Żarnowski T
Journal of Glaucoma 2019; 0: (IGR: 20-3)

80678 Topical application of polymeric nanomicelles in ophthalmology: a review on research efforts for the noninvasive delivery of ocular therapeutics
Nicoli S
Expert Opinion on Drug Delivery 2019; 16: 397-413 (IGR: 20-3)

81061 Tear Film, Conjunctival and Corneal Modifications Induced by Glaucoma Treatment
Oddone F
Current Medicinal Chemistry 2019; 0: (IGR: 20-3)

81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
Csutak A
Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)

80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension
Csutak A
Journal of Glaucoma 2019; 0: (IGR: 20-3)

80622 An in vivo confocal, prospective, masked, 36 months study on glaucoma patients medically treated with preservative-free or preserved monotherapy
Bianchi PE
Scientific reports 2019; 9: 4282 (IGR: 20-3)

81070 Co-delivery of latanoprost and timolol from micelles-laden contact lenses for the treatment of glaucoma
Yin T
Journal of Controlled Release 2019; 305: 18-28 (IGR: 20-3)

80528 Effect of 2 Novel Sustained-release Drug Release Systems on Bleb Fibrosis: An In Vivo Trabeculectomy Study in a Rabbit Model
Zhang Z
Journal of Glaucoma 2019; 28: 512-518 (IGR: 20-3)

81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
Jugaste T
Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)

80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension
Jugaste T
Journal of Glaucoma 2019; 0: (IGR: 20-3)

81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
Jugaste T
Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)

81070 Co-delivery of latanoprost and timolol from micelles-laden contact lenses for the treatment of glaucoma
He H
Journal of Controlled Release 2019; 305: 18-28 (IGR: 20-3)

80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension
Jugaste T
Journal of Glaucoma 2019; 0: (IGR: 20-3)

80528 Effect of 2 Novel Sustained-release Drug Release Systems on Bleb Fibrosis: An In Vivo Trabeculectomy Study in a Rabbit Model
Muddasani N
Journal of Glaucoma 2019; 28: 512-518 (IGR: 20-3)

81070 Co-delivery of latanoprost and timolol from micelles-laden contact lenses for the treatment of glaucoma
Zhang Y
Journal of Controlled Release 2019; 305: 18-28 (IGR: 20-3)

80528 Effect of 2 Novel Sustained-release Drug Release Systems on Bleb Fibrosis: An In Vivo Trabeculectomy Study in a Rabbit Model
Wall J
Journal of Glaucoma 2019; 28: 512-518 (IGR: 20-3)

81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
Volksone L
Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)

80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension
Volksone L
Journal of Glaucoma 2019; 0: (IGR: 20-3)

81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
Astakhov YS
Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)

80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension
Astakhov YS
Journal of Glaucoma 2019; 0: (IGR: 20-3)

80528 Effect of 2 Novel Sustained-release Drug Release Systems on Bleb Fibrosis: An In Vivo Trabeculectomy Study in a Rabbit Model
Satija C
Journal of Glaucoma 2019; 28: 512-518 (IGR: 20-3)

81070 Co-delivery of latanoprost and timolol from micelles-laden contact lenses for the treatment of glaucoma
Tang X
Journal of Controlled Release 2019; 305: 18-28 (IGR: 20-3)

80528 Effect of 2 Novel Sustained-release Drug Release Systems on Bleb Fibrosis: An In Vivo Trabeculectomy Study in a Rabbit Model
Greenberg E
Journal of Glaucoma 2019; 28: 512-518 (IGR: 20-3)

81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
Coupier L
Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)

80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension
Coupier L
Journal of Glaucoma 2019; 0: (IGR: 20-3)

81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
Coupier L
Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)

80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension
Coupier L
Journal of Glaucoma 2019; 0: (IGR: 20-3)

81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
Nordmann JP
Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)

80528 Effect of 2 Novel Sustained-release Drug Release Systems on Bleb Fibrosis: An In Vivo Trabeculectomy Study in a Rabbit Model
Mancera N
Journal of Glaucoma 2019; 28: 512-518 (IGR: 20-3)

80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension
Nordmann JP
Journal of Glaucoma 2019; 0: (IGR: 20-3)

81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
Stalmans I
Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)

80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension
Stalmans I
Journal of Glaucoma 2019; 0: (IGR: 20-3)

80528 Effect of 2 Novel Sustained-release Drug Release Systems on Bleb Fibrosis: An In Vivo Trabeculectomy Study in a Rabbit Model
Zurakowski D
Journal of Glaucoma 2019; 28: 512-518 (IGR: 20-3)

81207 Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension

Journal of Glaucoma 2019; 28: 498-506 (IGR: 20-3)

80754 Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension

Journal of Glaucoma 2019; 0: (IGR: 20-3)

80528 Effect of 2 Novel Sustained-release Drug Release Systems on Bleb Fibrosis: An In Vivo Trabeculectomy Study in a Rabbit Model
Ayyala RS
Journal of Glaucoma 2019; 28: 512-518 (IGR: 20-3)

79933 Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma
Arranz-Romera A
Journal of Controlled Release 2019; 297: 26-38 (IGR: 20-2)

80054 Co-Delivery of Timolol and Brimonidine with a Polymer Thin-Film Intraocular Device
Samy KE
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 124-131 (IGR: 20-2)

79378 Brinzolamide-loaded nanoemulsions: ex vivo transcorneal permeation, cell viability and ocular irritation tests
Mahboobian MM
Pharmaceutical Development and Technology 2019; 24: 600-606 (IGR: 20-2)

79363 Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications
Lazreg S
Journal Français d'Ophtalmologie 2018; 41: 945-954 (IGR: 20-2)

79769 Thermo-sensitive nanogel-laden bicontinuous microemulsion drug-eluting contact lenses
Lee SH
Journal of Biomedical Materials Research - Part B Applied Biomaterials 2019; 107: 1159-1169 (IGR: 20-2)

79383 Thermosensitive chitosan-gelatin-based hydrogel containing curcumin-loaded nanoparticles and latanoprost as a dual-drug delivery system for glaucoma treatment
Cheng YH
Experimental Eye Research 2019; 179: 179-187 (IGR: 20-2)

79765 Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study
Economou MA
Clinical Ophthalmology 2018; 12: 2399-2407 (IGR: 20-2)

80061 Effect of vitamin-E integration on delivery of prostaglandin analogs from therapeutic lenses
Sekar P
Journal of Colloid and Interface Science 2019; 539: 457-467 (IGR: 20-2)

79825 Engineering and Development of Chitosan-Based Nanocoatings for Ocular Contact Lenses
Mehta P
Journal of Pharmaceutical Sciences 2019; 108: 1540-1551 (IGR: 20-2)

79521 Local Delivery and Sustained-Release of Nitric Oxide Donor Loaded in Mesoporous Silica Particles for Efficient Treatment of Primary Open-Angle Glaucoma
Hu C
Advanced healthcare materials 2018; 7: e1801047 (IGR: 20-2)

79689 Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of the PG21 study of 0.4 µg daily microdose
Pasquale LR
Clinical Ophthalmology 2018; 12: 2451-2457 (IGR: 20-2)

80090 Rho kinase inhibitors for treatment of glaucoma
Mandell KJ
Expert Review of Ophthalmology 2011; 6: 611-622 (IGR: 20-2)

79583 Conjunctival Goblet Cells, the Overlooked Cells in Glaucoma Treatment
Tiedemann D
Journal of Glaucoma 2019; 28: 325-333 (IGR: 20-2)

79726 Gelatinized core liposomes: A new Trojan horse for the development of a novel timolol maleate glaucoma medication
Hathout RM
International Journal of Pharmaceutics 2019; 556: 192-199 (IGR: 20-2)

80027 Effect of gold nanoparticles on timolol uptake and its release kinetics from contact lenses: In vitro and in vivo evaluation
Maulvi FA
Acta biomaterialia 2019; 86: 350-362 (IGR: 20-2)

79766 Efficacy of the travoprost/timolol fixed combination versus the concomitant use of travoprost 0.004% and timolol 0.1% gel formulation
Kozobolis V
Clinical Ophthalmology 2018; 12: 2393-2398 (IGR: 20-2)

79583 Conjunctival Goblet Cells, the Overlooked Cells in Glaucoma Treatment
Mouhammad ZA
Journal of Glaucoma 2019; 28: 325-333 (IGR: 20-2)

79933 Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma
Davis BM
Journal of Controlled Release 2019; 297: 26-38 (IGR: 20-2)

79765 Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study
Laukeland HK
Clinical Ophthalmology 2018; 12: 2399-2407 (IGR: 20-2)

79521 Local Delivery and Sustained-Release of Nitric Oxide Donor Loaded in Mesoporous Silica Particles for Efficient Treatment of Primary Open-Angle Glaucoma
Sun J
Advanced healthcare materials 2018; 7: e1801047 (IGR: 20-2)

79689 Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of the PG21 study of 0.4 µg daily microdose
Lin S
Clinical Ophthalmology 2018; 12: 2451-2457 (IGR: 20-2)

79766 Efficacy of the travoprost/timolol fixed combination versus the concomitant use of travoprost 0.004% and timolol 0.1% gel formulation
Konstantinidis A
Clinical Ophthalmology 2018; 12: 2393-2398 (IGR: 20-2)

79825 Engineering and Development of Chitosan-Based Nanocoatings for Ocular Contact Lenses
Al-Kinani AA
Journal of Pharmaceutical Sciences 2019; 108: 1540-1551 (IGR: 20-2)

80027 Effect of gold nanoparticles on timolol uptake and its release kinetics from contact lenses: In vitro and in vivo evaluation
Patil RJ
Acta biomaterialia 2019; 86: 350-362 (IGR: 20-2)

79383 Thermosensitive chitosan-gelatin-based hydrogel containing curcumin-loaded nanoparticles and latanoprost as a dual-drug delivery system for glaucoma treatment
Ko YC
Experimental Eye Research 2019; 179: 179-187 (IGR: 20-2)

79726 Gelatinized core liposomes: A new Trojan horse for the development of a novel timolol maleate glaucoma medication
Gad HA
International Journal of Pharmaceutics 2019; 556: 192-199 (IGR: 20-2)

79769 Thermo-sensitive nanogel-laden bicontinuous microemulsion drug-eluting contact lenses
Kim HJ
Journal of Biomedical Materials Research - Part B Applied Biomaterials 2019; 107: 1159-1169 (IGR: 20-2)

80061 Effect of vitamin-E integration on delivery of prostaglandin analogs from therapeutic lenses
Chauhan A
Journal of Colloid and Interface Science 2019; 539: 457-467 (IGR: 20-2)

79378 Brinzolamide-loaded nanoemulsions: ex vivo transcorneal permeation, cell viability and ocular irritation tests
Seyfoddin A
Pharmaceutical Development and Technology 2019; 24: 600-606 (IGR: 20-2)

80054 Co-Delivery of Timolol and Brimonidine with a Polymer Thin-Film Intraocular Device
Cao Y
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 124-131 (IGR: 20-2)

79363 Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications
Merad Z
Journal Français d'Ophtalmologie 2018; 41: 945-954 (IGR: 20-2)

80090 Rho kinase inhibitors for treatment of glaucoma
Kudelka MR
Expert Review of Ophthalmology 2011; 6: 611-622 (IGR: 20-2)

79766 Efficacy of the travoprost/timolol fixed combination versus the concomitant use of travoprost 0.004% and timolol 0.1% gel formulation
Sideroudi H
Clinical Ophthalmology 2018; 12: 2393-2398 (IGR: 20-2)

79521 Local Delivery and Sustained-Release of Nitric Oxide Donor Loaded in Mesoporous Silica Particles for Efficient Treatment of Primary Open-Angle Glaucoma
Zhang Y
Advanced healthcare materials 2018; 7: e1801047 (IGR: 20-2)

79825 Engineering and Development of Chitosan-Based Nanocoatings for Ocular Contact Lenses
Arshad MS
Journal of Pharmaceutical Sciences 2019; 108: 1540-1551 (IGR: 20-2)

79583 Conjunctival Goblet Cells, the Overlooked Cells in Glaucoma Treatment
Utheim TP
Journal of Glaucoma 2019; 28: 325-333 (IGR: 20-2)

79689 Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of the PG21 study of 0.4 µg daily microdose
Weinreb RN
Clinical Ophthalmology 2018; 12: 2451-2457 (IGR: 20-2)

80027 Effect of gold nanoparticles on timolol uptake and its release kinetics from contact lenses: In vitro and in vivo evaluation
Desai AR
Acta biomaterialia 2019; 86: 350-362 (IGR: 20-2)

79363 Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications
Nouri MT
Journal Français d'Ophtalmologie 2018; 41: 945-954 (IGR: 20-2)

80090 Rho kinase inhibitors for treatment of glaucoma
Wirostko B
Expert Review of Ophthalmology 2011; 6: 611-622 (IGR: 20-2)

79933 Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma
Bravo-Osuna I
Journal of Controlled Release 2019; 297: 26-38 (IGR: 20-2)

79726 Gelatinized core liposomes: A new Trojan horse for the development of a novel timolol maleate glaucoma medication
Abdel-Hafez SM
International Journal of Pharmaceutics 2019; 556: 192-199 (IGR: 20-2)

79378 Brinzolamide-loaded nanoemulsions: ex vivo transcorneal permeation, cell viability and ocular irritation tests
Aboofazeli R
Pharmaceutical Development and Technology 2019; 24: 600-606 (IGR: 20-2)

80054 Co-Delivery of Timolol and Brimonidine with a Polymer Thin-Film Intraocular Device
Kim J
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 124-131 (IGR: 20-2)

79765 Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study
Grabska-Liberek I
Clinical Ophthalmology 2018; 12: 2399-2407 (IGR: 20-2)

79769 Thermo-sensitive nanogel-laden bicontinuous microemulsion drug-eluting contact lenses
Kim DH
Journal of Biomedical Materials Research - Part B Applied Biomaterials 2019; 107: 1159-1169 (IGR: 20-2)

79383 Thermosensitive chitosan-gelatin-based hydrogel containing curcumin-loaded nanoparticles and latanoprost as a dual-drug delivery system for glaucoma treatment
Chang YF
Experimental Eye Research 2019; 179: 179-187 (IGR: 20-2)

79363 Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications
Garout R
Journal Français d'Ophtalmologie 2018; 41: 945-954 (IGR: 20-2)

79769 Thermo-sensitive nanogel-laden bicontinuous microemulsion drug-eluting contact lenses
Chang WS
Journal of Biomedical Materials Research - Part B Applied Biomaterials 2019; 107: 1159-1169 (IGR: 20-2)

80027 Effect of gold nanoparticles on timolol uptake and its release kinetics from contact lenses: In vitro and in vivo evaluation
Shukla MR
Acta biomaterialia 2019; 86: 350-362 (IGR: 20-2)

79825 Engineering and Development of Chitosan-Based Nanocoatings for Ocular Contact Lenses
Singh N
Journal of Pharmaceutical Sciences 2019; 108: 1540-1551 (IGR: 20-2)

79583 Conjunctival Goblet Cells, the Overlooked Cells in Glaucoma Treatment
Dartt DA
Journal of Glaucoma 2019; 28: 325-333 (IGR: 20-2)